Multifunctional drugs for head injury

Robert Vink; Alan J Nimmo

doi:10.1016/j.nurt.2008.10.036

. 2009 Jan;6(1):28–42. doi: 10.1016/j.nurt.2008.10.036

Multifunctional drugs for head injury

Robert Vink ^1,^✉, Alan J Nimmo ¹

PMCID: PMC5084254 PMID: 19110197

Summary

Traumatic brain injury (TBI) remains one of the leading causes of mortality and morbidity worldwide in individuals under the age of 45 years, and, despite extensive efforts to develop neuroprotective therapies, there has been no successful outcome in any trial of neuroprotection to date. In addition to recognizing that many TBI clinical trials have not been optimally designed to detect potential efficacy, the failures can be attributed largely to the fact that most of the therapies investigated have been targeted toward an individual injury factor. The contemporary view of TBI is that of a very heterogenous type of injury, one that varies widely in etiology, clinical presentation, severity, and pathophysiology. The mechanisms involved in neuronal cell death after TBI involve an interaction of acute and delayed anatomic, molecular, biochemical, and physiological events that are both complex and multifaceted. Accordingly, neuropharmacotherapies need to be targeted at the multiple injury factors that contribute to the secondary injury cascade, and, in so doing, maximize the likelihood of a successful outcome. This review focuses on a number of such multifunctional compounds that have shown considerable success in experimental studies and that show maximum promise for success in clinical trials.

Key Words: Neurotrauma, statins, progesterone, erythropoietin, cyclosporin, toll-like receptors, magnesium, dexanabinol, bradykinin, substance P, minocycline, thyrotropin releasing hormone

References

1.Finfer SR, Cohen J. Severe traumatic brain injury. Resuscitation. 2001;48:77–90. doi: 10.1016/s0300-9572(00)00321-x. [DOI] [PubMed] [Google Scholar]
2.Kraus JF. Epidemiology of head injury. In: Cooper PR, editor. Head injury. 3rd ed. Baltimore: Williams & Wilkins; 1993. pp. 1–25. [Google Scholar]
3.Hillier SL, Hiller JE, Metzer J. Epidemiology of traumatic brain injury in South Australia. Brain Injury. 1997;11:649–659. doi: 10.1080/026990597123205. [DOI] [PubMed] [Google Scholar]
4.Mendelow AD, Crawford PJ. Primary and secondary brain injury. In: Reilly PL, Bullock R, editors. Head injury: pathophysiology and management of severe closed injury. 1st ed. London: Chapman & Hall; 1997. pp. 72–88. [Google Scholar]
5.McIntosh TK, Smith DH, Meaney DF, Kotapka MJ, Gennarelli TA, Graham DI. Neuropathological sequelae of traumatic brain injury: relationship to neurochemical and biomechanical mechanisms. Lab Invest. 1996;74:315–342. [PubMed] [Google Scholar]
6.Maas AI. Neuroprotective agents in traumatic brain injury. Expert Opin Investig Drugs. 2001;10:753–767. doi: 10.1517/13543784.10.4.753. [DOI] [PubMed] [Google Scholar]
7.Narayan RK, Michel ME, Ansell B, et al. Clinical Trials in Head Injury Study Group. J Neurotrauma. 2002;19:503–557. doi: 10.1089/089771502753754037. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Tolias CM, Bullock MR. Critical appraisal of neuroprotection trials in head injury: what have we learned? NeuroRx. 2004;1:71–79. doi: 10.1602/neurorx.1.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Faden AI. Neuroprotection and traumatic brain injury: theoretical option or realistic proposition? Curr Opin Neurol. 2002;15:707–712. doi: 10.1097/01.wco.0000044767.39452.bf. [DOI] [PubMed] [Google Scholar]
10.Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244:1360–1362. doi: 10.1126/science.2660263. [DOI] [PubMed] [Google Scholar]
11.Hickenbottom SL, Grotta J. Neuroprotective therapy. Semin Neurol. 1998;18:485–492. doi: 10.1055/s-2008-1040901. [DOI] [PubMed] [Google Scholar]
12.Gentile NT, McIntosh TK. Antagonists of excitatory amino acids and endogenous opioid peptides in the treatment of experimental central nervous systems injury. Ann Emerg Med. 1993;22:1028–1035. doi: 10.1016/s0196-0644(05)82746-5. [DOI] [PubMed] [Google Scholar]
13.Willis C, Lybrand S, Bellamy N. Excitatory amino acid inhibitors for traumatic brain injury. Cochrane Database Syst Rev. 2004; (l):CD003986. [DOI] [PMC free article] [PubMed]
14.Faden AI, Demediuk P, Panter SS, Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science. 1989;244:798–800. doi: 10.1126/science.2567056. [DOI] [PubMed] [Google Scholar]
15.Lea PM, Faden AI. Traumatic brain injury: developmental differences in glutamate receptor response and the impact on treatment. Ment Retard Dev Disabil Res Rev. 2001;7:235–248. doi: 10.1002/mrdd.1033. [DOI] [PubMed] [Google Scholar]
16.Haeberlein SL. Mitochondrial function in apoptotic neuronal cell death. Neurochem Res. 2004;29:521–530. doi: 10.1023/b:nere.0000014823.74782.b7. [DOI] [PubMed] [Google Scholar]
17.Signoretti S, Marmarou A, Aygok GA, Fatouros PP, Portella G, Bullock RM. Assessment of mitochondrial impairment in traumatic brain injury using high-resolution proton magnetic resonance spectroscopy. J Neurosurg. 2008;108:42–52. doi: 10.3171/JNS/2008/108/01/0042. [DOI] [PubMed] [Google Scholar]
18.Petronilli V, Penzo D, Scorrano L, Bemardi P, Di Lisa F. The mitochondrial permeability transition, release of cytochrome c and cell death: correlation with the duration of pore openings in situ. J Biol Chem. 2001;276:12030–12034. doi: 10.1074/jbc.M010604200. [DOI] [PubMed] [Google Scholar]
19.Hansson MJ, Månsson R, Mattiasson G, et al. Brain-derived respiring mitochondria exhibit homogeneous, complete and cyclosporin-sensitive permeability transition. J Neurochem. 2004;89:715–729. doi: 10.1111/j.1471-4159.2004.02400.x. [DOI] [PubMed] [Google Scholar]
20.Fiskum G. Mitochondrial participation in ischemic and traumatic neural cell death. J Neurotrauma. 2000;17:843–855. doi: 10.1089/neu.2000.17.843. [DOI] [PubMed] [Google Scholar]
21.Fiskum G. Mechanisms of neuronal death and neuroprotection. J Neurosurg Anesthesiol. 2004;16:108–110. doi: 10.1097/00008506-200401000-00025. [DOI] [PubMed] [Google Scholar]
22.Mattiasson G, Friberg H, Hansson M, Elmér E, Wieloch T. Flow cytometric analysis of mitochondria from CA1 and CA3 regions of rat hippocampus reveals differences in permeability transition pore activation. J Neurochem. 2003;87:532–544. doi: 10.1046/j.1471-4159.2003.02026.x. [DOI] [PubMed] [Google Scholar]
23.Lemasters JJ, Nieminen AL, Qian T, et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta. 1998;1366:177–196. doi: 10.1016/s0005-2728(98)00112-1. [DOI] [PubMed] [Google Scholar]
24.Xiong Y, Gu Q, Peterson PL, Muizelaar JP, Lee CP. Mitochondrial dysfunction and calcium pertubation induced by traumatic brain injury. J Neurotrauma. 1997;14:23–34. doi: 10.1089/neu.1997.14.23. [DOI] [PubMed] [Google Scholar]
25.Clausen T, Zauner A, Levasseur JE, Rice AC, Bullock R. Induced mitochondrial failure in the feline brain: implications for understanding acute post-traumatic metabolic events. Brain Res. 2001;908:35–48. doi: 10.1016/s0006-8993(01)02566-5. [DOI] [PubMed] [Google Scholar]
26.Cernak I, Savic VJ, Kotur J, Prokic V, Veljovic M, Grbovic D. Characterization of plasma magnesium concentration and oxidative stress following graded traumatic brain injury in humans. J Neurotrauma. 2000;17:53–68. doi: 10.1089/neu.2000.17.53. [DOI] [PubMed] [Google Scholar]
27.Ikeda Y, Long DM. The molecular basis of brain injury and brain edema: the role of oxygen free radicals. Neurosurgery. 1990;27:1–11. doi: 10.1097/00006123-199007000-00001. [DOI] [PubMed] [Google Scholar]
28.Lewén A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma. 2000;17:871–890. doi: 10.1089/neu.2000.17.871. [DOI] [PubMed] [Google Scholar]
29.Shohami E, Beit-Yannai E, Horowitz M, Kohen R. Oxidative stress in closed-head injury: brain antioxidant capacity as an indicator of functional outcome. J Cereb Blood Flow Metab. 1997;17:1007–1019. doi: 10.1097/00004647-199710000-00002. [DOI] [PubMed] [Google Scholar]
30.Hall ED, Yonkers PA, Andrus PK, Cox JW, Anderson DK. Biochemistry and pharmacology of lipid antioxidants in acute brain and spinal cord injury. J Neurotrauma. 1992;9:S425–S442. [PubMed] [Google Scholar]
31.Marklund N, Clausen F, Lewander T, Hillered L. Monitoring of reactive oxygen species production after traumatic brain injury in rats with microdialysis and the 4-hydroxybenzoic acid trapping method. J Neurotrauma. 2001;18:1217–1227. doi: 10.1089/089771501317095250. [DOI] [PubMed] [Google Scholar]
32.Morganti-Kossmann MC, Satgunaseelan L, Bye N, Kossmann T. Modulation of immune response by head injury. Injury. 2007;38:1360–1362. doi: 10.1016/j.injury.2007.10.005. [DOI] [PubMed] [Google Scholar]
33.Israelsson C, Bengtsson H, Kylberg A, et al. Distinct cellular patterns of upregulated chemokine expression supporting a prominent inflammatory role in traumatic brain injury. J Neurotrauma. 2008;25:959–974. doi: 10.1089/neu.2008.0562. [DOI] [PubMed] [Google Scholar]
34.Craft JM, Watterson DM, Van Eldik LJ. Neuroinflammation: a potential therapeutic target. Expert Opin Ther Targets. 2005;9:887–900. doi: 10.1517/14728222.9.5.887. [DOI] [PubMed] [Google Scholar]
35.Habgood MD, Bye N, Dziegielewska KM, et al. Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice. Eur J Neurosci. 2007;25:231–238. doi: 10.1111/j.1460-9568.2006.05275.x. [DOI] [PubMed] [Google Scholar]
36.Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16:1–13. doi: 10.1016/j.nbd.2003.12.016. [DOI] [PubMed] [Google Scholar]
37.Nimmo AJ, Cernak I, Heath DL, Hu X, Bennett CJ, Vink R. Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. Neuropeptides. 2004;38:40–47. doi: 10.1016/j.npep.2003.12.003. [DOI] [PubMed] [Google Scholar]
38.Krizanac-Bengez L, Mayberg MR, Janigro D. The cerebral vasculature as a therapeutic target for neurological disorders and the role of shear stress in vascular homeostatis [sic] and pathophysiology. Neurol Res. 2004;26:846–853. doi: 10.1179/016164104X3789. [DOI] [PubMed] [Google Scholar]
39.Klatzo I. Brain Edema. In: Odom GL, editor. Central nervous system trauma research status report. Washington, DC: National Institutes of Health; 1979. pp. 110–112. [Google Scholar]
40.Baskaya MK, Dogan A, Rao AM, Dempsey RJ. Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. J Neurosurg. 2000;92:448–452. doi: 10.3171/jns.2000.92.3.0448. [DOI] [PubMed] [Google Scholar]
41.Kimelberg HK. Current concepts of brain edema: review of laboratory investigations. J Neurosurg. 1995;83:1051–1059. doi: 10.3171/jns.1995.83.6.1051. [DOI] [PubMed] [Google Scholar]
42.Stover JF, Unterberg AW. Increased cerebrospinal fluid glutamate and taurine concentrations are associated with traumatic brain edema formation in rats. Brain Res. 2000;875:51–55. doi: 10.1016/s0006-8993(00)02597-x. [DOI] [PubMed] [Google Scholar]
43.Duvdevani R, Roof RL, Fulop Z, Hoffman SW, Stein DG. Blood-brain barrier breakdown and edema formation following frontal cortical contusion: does hormonal status play a role? J Neurotrauma. 1995;12:65–75. doi: 10.1089/neu.1995.12.65. [DOI] [PubMed] [Google Scholar]
44.Graham DI. Neuropathology of head injury. In: Narayan RK, Wilberger JE, Povlishock JT, editors. Neurotrauma. New York: McGraw-Hill; 1996. [Google Scholar]
45.Treggiari MM, Schutz N, Yanez ND, Romand JA. Role of intracranial pressure values and patterns in predicting outcome in traumatic brain injury: a systematic review. Neurocrit Care. 2007;6:104–112. doi: 10.1007/s12028-007-0012-1. [DOI] [PubMed] [Google Scholar]
46.Carter BG, Butt W, Taylor A. ICP and CPP: excellent predictors of long term outcome in severely brain injured children. Childs Nerv Syst. 2008;24:245–251. doi: 10.1007/s00381-007-0461-z. [DOI] [PubMed] [Google Scholar]
47.Walberer M, Ritschel N, Nedelmann M, et al. Aggravation of infarct formation by brain swelling in a large territorial stroke: a target for neuroprotection? J Neurosurg. 2008;109:287–293. doi: 10.3171/JNS/2008/109/8/0287. [DOI] [PubMed] [Google Scholar]
48.Reilly PL. Management of intracranial pressure and cerebral perfusion. In: Reilly PL, Bullock R, editors. Head injury: pathophysiology and management of severe closed injury. 1st ed. London: Chapman & Hall; 1997. pp. 385–406. [Google Scholar]
49.Reiss AB, Wirkowski E. Role of HMG-CoA reductase inhibitors in neurological disorders: progress to date. Drugs. 2007;67:2111–2120. doi: 10.2165/00003495-200767150-00001. [DOI] [PubMed] [Google Scholar]
50.Rajanikant GK, Zemke D, Kassab M, Majid A. The therapeutic potential of statins in neurological disorders. Curr Med Chem. 2007;14:103–112. doi: 10.2174/092986707779313462. [DOI] [PubMed] [Google Scholar]
51.Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/ Rho-kinase and Akt pathways. Circulation. 2002;105:1756–1759. doi: 10.1161/01.cir.0000015465.73933.3b. [DOI] [PubMed] [Google Scholar]
52.Maeda T, Kawane T, Horiuchi N. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology. 2003;144:681–692. doi: 10.1210/en.2002-220682. [DOI] [PubMed] [Google Scholar]
53.Delanty N, Vaughan CJ, Sheehy N. Statins and neuroprotection. Expert Opin Investig Drugs. 2001;10:1847–1853. doi: 10.1517/13543784.10.10.1847. [DOI] [PubMed] [Google Scholar]
54.Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol. 2003;58:719–731. doi: 10.1007/s00228-002-0556-0. [DOI] [PubMed] [Google Scholar]
55.Zacco A, Togo J, Spence K, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci. 2003;23:11104–11111. doi: 10.1523/JNEUROSCI.23-35-11104.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
56.Bösel J, Gandor F, Harms C, et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem. 2005;92:1386–1398. doi: 10.1111/j.1471-4159.2004.02980.x. [DOI] [PubMed] [Google Scholar]
57.Dolga AM, Nijholt IM, Ostroveanu A, Ten Bosch Q, Luiten PG, Eisel UL. Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J Alzheimers Dis. 2008;13:111–122. doi: 10.3233/jad-2008-13201. [DOI] [PubMed] [Google Scholar]
58.Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53:743–751. doi: 10.1002/ana.10555. [DOI] [PubMed] [Google Scholar]
59.Lu D, Mahmood A, Goussev A, et al. Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury. J Neurosurg. 2004;101:813–821. doi: 10.3171/jns.2004.101.5.0813. [DOI] [PubMed] [Google Scholar]
60.Lu D, Qu C, Goussev A, et al. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma. 2007;24:1132–1146. doi: 10.1089/neu.2007.0288. [DOI] [PMC free article] [PubMed] [Google Scholar]
61.Franke C, Noldner M, Abdel-Kader R, et al. Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiol Dis. 2007;25:438–445. doi: 10.1016/j.nbd.2006.10.004. [DOI] [PubMed] [Google Scholar]
62.Pannu R, Christic DK, Barbosa E, Singh I, Singh AK. Posttrauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury. J Neurochem. 2007;101:182–200. doi: 10.1111/j.1471-4159.2006.04354.x. [DOI] [PubMed] [Google Scholar]
63.Cimino M, Gelosa P, Gianella A, Nobili E, Tremoli E, Sironi L. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist. 2007;13:208–213. doi: 10.1177/1073858406297121. [DOI] [PubMed] [Google Scholar]
64.Paintlia AS, Paintlia MK, Singh I, Skoff RB, Singh AK. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia 2008 Aug. 20 [Epub ahead of print]. [DOI] [PMC free article] [PubMed]
65.Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 1999;22:410–416. doi: 10.1016/s0166-2236(99)01399-5. [DOI] [PubMed] [Google Scholar]
66.Komeyev A, Costa E. Allopregnanolone (THP) mediates anesthetic effects of progesterone in rat brain. Horm Behav. 1996;30:37–43. doi: 10.1006/hbeh.1996.0006. [DOI] [PubMed] [Google Scholar]
67.Rodgers RJ, Johnson NJ. Behaviorally selective effects of neuroactive steroids on plus-maze anxiety in mice. Pharmacol Biochem Behav. 1998;59:221–232. doi: 10.1016/s0091-3057(97)00339-0. [DOI] [PubMed] [Google Scholar]
68.Frye CA, Walf AA, Rhodes ME, Hamey JP. Progesterone enhances motor, anxiolytic, analgesic, and antidepressive behavior of wild-type mice, but not those deficient in type 1 5α-reductase. Brain Res. 2004;1004:116–124. doi: 10.1016/j.brainres.2004.01.020. [DOI] [PubMed] [Google Scholar]
69.Gonzalez Deniselle MC, Costa JJL, Gonzalez SL, et al. Basis of progesterone protection in spinal cord neurodegeneration. J Steroid Biochem Mol Biol. 2002;83:199–209. doi: 10.1016/s0960-0760(02)00262-5. [DOI] [PubMed] [Google Scholar]
70.Kumon Y, Soon CK, Tompkins P, Stevens Al, Sakaki S, Loftus M. Neuroprotective effect of postischemic administration of progesterone in spontaneously hypertensive rats with focal cerebral ischemia. J Neurosurg. 2000;92:848–852. doi: 10.3171/jns.2000.92.5.0848. [DOI] [PubMed] [Google Scholar]
71.Jiang N, Chopp M, Stein D, Feit H. Progesterone is neuroprotective after transient middle cerebral occlusion in male rats. Brain Res. 1996;735:101–107. doi: 10.1016/0006-8993(96)00605-1. [DOI] [PubMed] [Google Scholar]
72.Vongher J, Frye C. Progesterone in conjunction with estradiol has neuroprotective effects in an animal model of neurodegeneration. Pharmacol Biochem Behav. 1999;64:777–785. doi: 10.1016/s0091-3057(99)00140-9. [DOI] [PubMed] [Google Scholar]
73.Roof RL, Hall ED. Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. J Neurotrauma. 2000;17:367–388. doi: 10.1089/neu.2000.17.367. [DOI] [PubMed] [Google Scholar]
74.Ogata T, Nakamura Y, Tsuji K, Shibata T, Kataoka K. Steroid hormones protect spinal cord neurons from glutamate toxicity. Neuroscience. 1993;55:445–449. doi: 10.1016/0306-4522(93)90513-f. [DOI] [PubMed] [Google Scholar]
75.Paul SM, Purdy RH. Neuroactive steroids. FASEB J. 1992;6:2311–2322. [PubMed] [Google Scholar]
76.Thomas AJ, Nockles RP, Hiu QP, Shaffrey CI, Chopp M. Progesterone is neuroprotective after acute experimental spinal cord trauma in rats. Spine. 1999;24:2134–2138. doi: 10.1097/00007632-199910150-00013. [DOI] [PubMed] [Google Scholar]
77.Labombarda F, Gonzalez SL, Gonzalez Deniselle MC, Guennoun R, Schumacher M, de Nicola AF. Cellular basis for progesterone neuroprotection in the injured spinal cord. J Neurotrauma. 2002;19:343–355. doi: 10.1089/089771502753594918. [DOI] [PubMed] [Google Scholar]
78.Gonzalez-Vidal MD, Cervera-Gaviria M, Ruelas R, Escobar A, Moralí G, Cervantes M. Progesterone: protective effects on the cat hippocampal neuronal damage due to acute global cerebral ischemia. Arch Med Res. 1998;28:117–124. [PubMed] [Google Scholar]
79.Koenig HL, Gong WH, Pelissier P. Role of progesterone in peripheral nerve repair. Rev Reprod. 2000;5:189–199. doi: 10.1530/ror.0.0050189. [DOI] [PubMed] [Google Scholar]
80.Gruber CJ, Huber JC. Differential effects of progestins on the brain. Maturitas. 2003;46(Suppl 1):S71–S75. doi: 10.1016/j.maturitas.2003.09.021. [DOI] [PubMed] [Google Scholar]
81.Roof RL, Zhang Q, Glasier MM, Stein DG. Gender-specific impairment on Morris water maze task after entorhinal cortex lesion. Behav Brain Res. 1993;57:47–51. doi: 10.1016/0166-4328(93)90060-4. [DOI] [PubMed] [Google Scholar]
82.Roof RL, Duvdevani R, Braswell L, Stein DG. Progesterone facilitates cognitive recovery and reduces secondary neuronal loss caused by cortical contusion injury in male rats. Exp Neurol. 1994;129:64–69. doi: 10.1006/exnr.1994.1147. [DOI] [PubMed] [Google Scholar]
83.Shear DA, Galani R, Hoffman SW, Stein DG. Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp Neurol. 2002;178:59–67. doi: 10.1006/exnr.2002.8020. [DOI] [PubMed] [Google Scholar]
84.He J, Hoffman SW, Stein DG. Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury. Restor Neurol Neurosci. 2004;22:19–31. [PubMed] [Google Scholar]
85.Roof RL, Hoffman SW, Stein DG. Progesterone protects against lipid peroxidation following traumatic brain injury in rats. Mol Chem Neuropathol. 1997;31:1–11. doi: 10.1007/BF02815156. [DOI] [PubMed] [Google Scholar]
86.Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurones. J Neurochem. 1996;66:1836–1844. doi: 10.1046/j.1471-4159.1996.66051836.x. [DOI] [PubMed] [Google Scholar]
87.Smith SS. Progesterone administration attenuates excitatory amino acid responses of cerebellar Purkinje cells. Neuroscience. 1991;42:309–320. doi: 10.1016/0306-4522(91)90377-z. [DOI] [PubMed] [Google Scholar]
88.Cai W, Zhu Y, Furuya K, Li Z, Sokabe M, Chen L. Two different molecular mechanisms underlying progesterone neuroprotection against ischemic brain damage. Neuropharmacology. 2008;55:127–138. doi: 10.1016/j.neuropharm.2008.04.023. [DOI] [PubMed] [Google Scholar]
89.Djebaili M, Hoffman SW, Stein DG. Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. Neuroscience. 2004;123:349–359. doi: 10.1016/j.neuroscience.2003.09.023. [DOI] [PubMed] [Google Scholar]
90.O’Connor CA, Cernak I, Johnson F, Vink R. Effects of progesterone on neurologic and morphologic outcome following diffuse traumatic brain injury in rats. Exp Neurol. 2007;205:145–153. doi: 10.1016/j.expneurol.2007.01.034. [DOI] [PubMed] [Google Scholar]
91.Pettus EH, Wright DW, Stein DG, Hoffman SW. Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. Brain Res. 2005;1049:112–119. doi: 10.1016/j.brainres.2005.05.004. [DOI] [PubMed] [Google Scholar]
92.Roof RL, Duvdevani R, Stein DG. Progesterone treatment attenuates brain edema following contusion injury in male and female rats. Restor Neurol Neurosci. 1992;4:425–427. doi: 10.3233/RNN-1992-4608. [DOI] [PubMed] [Google Scholar]
93.O’Connor CA, Cernak I, Vink R. Both estrogen and progesterone attenuate edema formation following diffuse traumatic brain injury in rats. Brain Res. 2005;1062:171–174. doi: 10.1016/j.brainres.2005.09.011. [DOI] [PubMed] [Google Scholar]
94.Roof RL, Duvdevani R, Heybum JW, Stein DG. Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective. Exp Neurol. 1996;138:246–251. doi: 10.1006/exnr.1996.0063. [DOI] [PubMed] [Google Scholar]
95.Wright DW, Bauer ME, Hoffman SW, Stein DG. Serum progesterone levels correlate with decreased cerebral edema after traumatic brain injury in male rats. J Neurotrauma. 2001;18:901–909. doi: 10.1089/089771501750451820. [DOI] [PubMed] [Google Scholar]
96.Limmroth V, Lee WS, Moskowitz MA. GABAA-receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges. Br J Pharmacol. 1996;117:99–104. doi: 10.1111/j.1476-5381.1996.tb15160.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
97.Kuebler JF, Yokoyama Y, Jarrar D, et al. Administration of progesterone after trauma and hemorrhagic shock prevents hepatocellular injury. Arch Surg. 2003;138:727–734. doi: 10.1001/archsurg.138.7.727. [DOI] [PubMed] [Google Scholar]
98.Kuebler JF, Jarrar D, Bland KI, Rue L, Wang P, Chaudry IH. Progesterone administration after trauma and hemorrhagic shock improves cardiovascular responses. Crit Care Med. 2003;31:1786–1793. doi: 10.1097/01.CCM.0000063441.41446.23. [DOI] [PubMed] [Google Scholar]
99.Wright DW, Kellermann AL, Hertzberg VS, et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med. 2007;49:391–402. doi: 10.1016/j.annemergmed.2006.07.932. [DOI] [PubMed] [Google Scholar]
100.Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care. 2008;12:R61–R61. doi: 10.1186/cc6887. [DOI] [PMC free article] [PubMed] [Google Scholar]
101.Lapchak PA. Carbamylated erythropoietin to treat neuronal injury: new development strategies. Expert Opin Investig Drugs. 2008;17:1175–1186. doi: 10.1517/13543784.17.8.1175. [DOI] [PubMed] [Google Scholar]
102.Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A. 2000;97:10526–10531. doi: 10.1073/pnas.97.19.10526. [DOI] [PMC free article] [PubMed] [Google Scholar]
103.Grasso G, Sfacteria A, Meli F, Fodale V, Buemi M, Iacopino DG. Neuroprotection by erythropoietin administration after experimental traumatic brain injury. Brain Res. 2007;1182:99–105. doi: 10.1016/j.brainres.2007.08.078. [DOI] [PubMed] [Google Scholar]
104.Cherian L, Goodman JC, Robertson C. Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats. J Pharmacol Exp Ther. 2007;322:789–794. doi: 10.1124/jpet.107.119628. [DOI] [PubMed] [Google Scholar]
105.Elfar JC, Jacobson JA, Puzas JE, Rosier RN, Zuscik MJ. Erythropoietin accelerates functional recovery after peripheral nerve injury. J Bone Joint Surg Am. 2008;90:1644–1653. doi: 10.2106/JBJS.G.00557. [DOI] [PMC free article] [PubMed] [Google Scholar]
106.Xiong Y, Lu D, Qu C, et al. Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice. J Neurosurg. 2008;109:510–521. doi: 10.3171/JNS/2008/109/9/0510. [DOI] [PMC free article] [PubMed] [Google Scholar]
107.Yuan RR, Li WP, Menonna J, Maeda Y, Dowling PC. Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators 2007: International Application Number PCT/ 1B2006/003581. Patent Publication Number WO2007052154 (A2). Available at: http://v3.espacenet.com/publicationDetails/biblio? KC=A2&date=20070510&NR=2007052154A2&DB=EPODOC&locale=en_EP&CC=WO&FT=D.
108.King CE, Rodger J, Bartlett C, Esmaili T, Dunlop SA, Beazley LD. Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection. Exp Neurol. 2007;205:48–55. doi: 10.1016/j.expneurol.2007.01.017. [DOI] [PubMed] [Google Scholar]
109.Xiong Y, Mahmood A, Lu D, et al. Histological and functional outcomes after traumatic brain injury in mice null for the erythropoietin receptor in the central nervous system. Brain Res. 2008;1230:247–257. doi: 10.1016/j.brainres.2008.06.127. [DOI] [PMC free article] [PubMed] [Google Scholar]
110.Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem. 2005;94:819–827. doi: 10.1111/j.1471-4159.2005.03219.x. [DOI] [PubMed] [Google Scholar]
111.Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery. 2001;48:1393–1399. doi: 10.1097/00006123-200106000-00051. [DOI] [PubMed] [Google Scholar]
112.Wells JE, Huribert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain. 2003;126:1628–1637. doi: 10.1093/brain/awg178. [DOI] [PubMed] [Google Scholar]
113.Teng YD, Choi H, Onario RC, et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A. 2004;101:3071–3076. doi: 10.1073/pnas.0306239101. [DOI] [PMC free article] [PubMed] [Google Scholar]
114.Yune TY, Lee JY, Jung GY, et al. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J Neurosci. 2007;27:7751–7761. doi: 10.1523/JNEUROSCI.1661-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
115.Fan LW, Pang Y, Lin S, et al. Minocycline reduces lipopolysaccharide-induced neurological dysfunction and brain injury in the neonatal rat. J Neurosci Res. 2005;82:71–82. doi: 10.1002/jnr.20623. [DOI] [PubMed] [Google Scholar]
116.Bye N, Habgood MD, Callaway JK, et al. Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. Exp Neurol. 2007;204:220–233. doi: 10.1016/j.expneurol.2006.10.013. [DOI] [PubMed] [Google Scholar]
117.Carty ML, Wixey JA, Colditz PB, Buller KM. Post-insult minocycline treatment attenuates hypoxia-ischemia-induced neuroinflammation and white matter injury in the neonatal rat: a comparison of two different dose regimens. Int J Dev Neurosci. 2008;26:477–485. doi: 10.1016/j.ijdevneu.2008.02.005. [DOI] [PubMed] [Google Scholar]
118.Chung KF. Drugs to suppress cough. Expert Opin Investig Drugs. 2005;14:19–27. doi: 10.1517/13543784.14.1.19. [DOI] [PubMed] [Google Scholar]
119.Rodi D, Couture R, Ongali B, Simonato M. Targeting kinin receptors for the treatment of neurological diseases. Curr Pharm Des. 2005;11:1313–1326. doi: 10.2174/1381612053507422. [DOI] [PubMed] [Google Scholar]
120.Noda M, Kariura Y, Pannasch U, et al. Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia. J Neurochem. 2007;101:397–410. doi: 10.1111/j.1471-4159.2006.04339.x. [DOI] [PubMed] [Google Scholar]
121.Kaplanski J, Pruneau D, Asa I, et al. LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats. J Neurotrauma. 2002;19:953–964. doi: 10.1089/089771502320317104. [DOI] [PubMed] [Google Scholar]
122.Marmarou A, Nichols J, Burgess J, et al. American Brain Injury Consortium Study Group. Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. J Neurotrauma. 1999;16:431–444. doi: 10.1089/neu.1999.16.431. [DOI] [PubMed] [Google Scholar]
123.Maggi CA. Pharmacology of the efferent function of primary sensory neurons. In: Geppetti P, Holzer P, editors. Neurogenic inflammation. Boca Raton, FL: CRC Press; 1996. [Google Scholar]
124.Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998;281:1640–1645. doi: 10.1126/science.281.5383.1640. [DOI] [PubMed] [Google Scholar]
125.Nessler S, Stadelmann C, Bittner A, et al. Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist: a putative role for substance P in CNS inflammation. J Neuroimmunol. 2006;179:1–8. doi: 10.1016/j.jneuroim.2006.06.026. [DOI] [PubMed] [Google Scholar]
126.Reardon K, Heath DL, Nimmo AJ, Vink R, Whitfield K. Inhibition of neurogenic inflammation attenuates the inflammatory response following traumatic brain injury in rats. In: 7th International Neurotrauma Symposium. Bologna: Medimond International Proceedings, 2004:115–118.
127.Donkin JJ, Turner RJ, Hassan I, Vink R. Substance P in traumatic brain injury. Prog Brain Res. 2007;161:97–109. doi: 10.1016/S0079-6123(06)61007-8. [DOI] [PubMed] [Google Scholar]
128.Alvaro G, Di Fabio R. Neurokinin 1 receptor antagonists: current prospects. Curr Opin Drug Discov Devel. 2007;10:613–621. [PubMed] [Google Scholar]
129.Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675–680. doi: 10.1038/90609. [DOI] [PubMed] [Google Scholar]
130.Marsh BJ, Stenzel-Poore MP. Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases. Curr Opin Pharmacol. 2008;8:8–13. doi: 10.1016/j.coph.2007.09.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
131.Van Noort JM, Bsibsi M. Use of TLR3 agonists for treatment of neurodegenerative disorders 2007, Patent Application Number WO2007089151 [Available at: http://www.wipo.int/pctdb/en/wo. jsp?wo=2007089151].
132.Boivin N, Sergeric Y, Rivest S, Boivin G. Effect of pretreatment with Toll-like receptor agonists in a mouse model of Herpes simplex virus type 1 encephalitis. J Infect Dis. 2008;198:664–672. doi: 10.1086/590671. [DOI] [PubMed] [Google Scholar]
133.Pop E. Dexanabinol Pharmos. Curr Opin Investig Drugs. 2000;1:494–503. [PubMed] [Google Scholar]
134.Darlington CL. Dexanabinol: a novel cannabinoid with neuroprotective properties. IDrugs. 2003;6:976–979. [PubMed] [Google Scholar]
135.Shohami E, Novikov M, Mechoulam R. A nonpsychotropic cannabinoid, HU-211, has cerebrovascular effects after closed head injury in the rat. J Neurotrauma. 1993;10:109–119. doi: 10.1089/neu.1993.10.109. [DOI] [PubMed] [Google Scholar]
136.Belayev L, Busto R, Zhao W, Ginsberg MD. HU-211, a novel noncompetitive N-methyl-d-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke. 1995;26:2313–2319. doi: 10.1161/01.str.26.12.2313. [DOI] [PubMed] [Google Scholar]
137.Feigenbaum JJ, Bergmann F, Richmond SA, et al. Nonpsychotropic cannabinoid acts as a functional N-methyl-d-aspartate receptor blocker. Proc Natl Acad Sci U S A. 1989;86:9584–9987. doi: 10.1073/pnas.86.23.9584. [DOI] [PMC free article] [PubMed] [Google Scholar]
138.Eshhar N, Striem S, Kohen R, Tirosh O, Biegon A. Neuroprotectant and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur J Pharmacol. 1995;283:19–29. doi: 10.1016/0014-2999(95)00271-l. [DOI] [PubMed] [Google Scholar]
139.Shohami E, Gallily R, Mechoulam R, Bass R, Ben Hur T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant. J Neuroimmunol. 1997;72:169–177. doi: 10.1016/s0165-5728(96)00181-6. [DOI] [PubMed] [Google Scholar]
140.Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med. 2002;8:58–61. doi: 10.1016/s1471-4914(02)02276-1. [DOI] [PubMed] [Google Scholar]
141.Knoller N, Levi L, Shoshan I, et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med. 2002;30:548–554. doi: 10.1097/00003246-200203000-00009. [DOI] [PubMed] [Google Scholar]
142.Maas AI, Murray G, Henney H, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 2006;5:38–45. doi: 10.1016/S1474-4422(05)70253-2. [DOI] [PubMed] [Google Scholar]
143.Vink R, Nimmo AJ. Novel therapies in development for the treatment of traumatic brain injury. Expert Opin Investig Drugs. 2002;11:1375–1386. doi: 10.1517/13543784.11.10.1375. [DOI] [PubMed] [Google Scholar]
144.Hoane MR. Assessment of cognitive function following magnesium therapy in the traumatically injured brain. Magnes Res. 2007;20:229–236. [PubMed] [Google Scholar]
145.Meloni BP, Zhu H, Knuckey NW. Is magnesium neuroprotective following global and focal cerebral ischaemia? A review of published studies. Magnes Res. 2006;19:123–137. [PubMed] [Google Scholar]
146.Haupt H, Scheibe F, Mazurek B. Therapeutic efficacy of magnesium in acoustic trauma in the guinea pig. ORL J Otorhinolaryngol Relat Spec. 2003;65:134–139. doi: 10.1159/000072250. [DOI] [PubMed] [Google Scholar]
147.Hoane MR, Knotts AA, Akstulewicz SL, Aquilano M, Means LW. The behavioral effects of magnesium therapy on recovery of function following bilateral anterior medial cortex lesions in the rat. Brain Res Bull. 2003;15:105–114. doi: 10.1016/s0361-9230(03)00022-4. [DOI] [PubMed] [Google Scholar]
148.Türkyilmaz C, Türkyilmaz Z, Atalay Y, Söylemezoglu F, Celasun B. Magnesium pre-treatment reduces neuronal apoptosis in newborn rats in hypoxia-ischemia. Brain Res. 2002;955:133–137. doi: 10.1016/s0006-8993(02)03395-4. [DOI] [PubMed] [Google Scholar]
149.Tang YN, Zhao FL, Ye HM. Expression of caspase-3 mRNA in the hippocampus of seven-day-old hypoxic-ischemic rats and the mechanism of neural protection with magnesium sulfate [In Chinese] Zhonghua Er Ke Za Zhi. 2003;41:212–214. [PubMed] [Google Scholar]
150.Gee JB, Corbett RJ, Perlman J, Laptook AR. The effects of systemic magnesium sulfate infusion on brain magnesium concentrations and energy state during hypoxia-ischemia in newborn miniswine. Pediatr Res. 2004;55:93–100. doi: 10.1203/01.PDR.0000099771.39629.E5. [DOI] [PubMed] [Google Scholar]
151.Lee JS, Han YM, Yoo do S, et al. A molecular basis for the efficacy of magnesium treatment following traumatic brain injury in rats. J Neurotrauma. 2004;21:549–561. doi: 10.1089/089771504774129883. [DOI] [PubMed] [Google Scholar]
152.Xu M, Dai W, Deng X. Effects on magnesium sulfate on brain mitochondrial respiratory function in rats after experimental traumatic brain injury. Chin J Traumatol. 2002;5:361–364. [PubMed] [Google Scholar]
153.Sang N, Meng Z. Blockade by magnesium of sodium currents in accutely isolated hippocampal CA1 neurons of rat. Brain Res. 2002;18:218–221. doi: 10.1016/s0006-8993(02)03217-1. [DOI] [PubMed] [Google Scholar]
154.Okiyama K, Smith DH, Gennarelli TA, Simon RP, Leach M, McIntosh TK. The sodium channel blocker and glutamate release inhibitor BW1003C87 and magnesium attenuate regional cerebral edema following experimental brain injury in the rat. J Neurochem. 1995;64:802–809. doi: 10.1046/j.1471-4159.1995.64020802.x. [DOI] [PubMed] [Google Scholar]
155.Kahraman S, Ozgurtas T, Kayali H, Atabey C, Kutluay T, Timurkaynak E. Monitoring of serum ionized magnesium in neurosurgical intensive care unit: preliminary results. Clin Chem Acta. 2003;334:211–215. doi: 10.1016/s0009-8981(03)00235-3. [DOI] [PubMed] [Google Scholar]
156.van den Burgh WM, Algra A, van der Sprenkel JW, Tullenken CA, Rinkel GJ. Hypomagnesia after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2003;52:276–281. doi: 10.1227/01.neu.0000043984.42487.0e. [DOI] [PubMed] [Google Scholar]
157.Stippler M, Fischer MR, Puccio AM, et al. Serum and cerebrospinal fluid magnesium in severe traumatic brain injury outcome. J Neurotrauma. 2007;24:1347–1354. doi: 10.1089/neu.2007.0277. [DOI] [PubMed] [Google Scholar]
158.Kafadar AM, Sanus GZ, Is M, et al. Prolonged elevation of magnesium in the cerebrospinal fluid of patients with severe head injury. Neurol Res. 2007;29:824–829. doi: 10.1179/016164107X181879. [DOI] [PubMed] [Google Scholar]
159.Heath DL, Vink R. Subdural hematoma following traumatic brain injury causes a secondary decline in brain free magnesium concentration. J Neurotrauma. 2001;18:465–469. doi: 10.1089/089771501750171074. [DOI] [PubMed] [Google Scholar]
160.Altura BM, Kostellow AB, Zhang A, et al. Expression of the nuclear factor-κB and proto-oncogenes c-fos and c-jun are induced by low extracellular Mg2+ in aortic and cerebral vascular smooth muscle cells: possible links to hypertension, atherogenesis and stroke. Am J Hypertension. 2003;16:701–707. doi: 10.1016/s0895-7061(03)00987-7. [DOI] [PubMed] [Google Scholar]
161.McKee JA, Brewer RP, Macy GE, et al. Analysis of the brain bioavailability of peripherally administered magnesium sulfate: a study in humans with acute brain injury undergoing prolonged induced hypermagnesemia. Crit Care Med. 2005;33:661–666. doi: 10.1097/01.ccm.0000156293.35868.b2. [DOI] [PubMed] [Google Scholar]
162.Temkin NR, Anderson GD, Winn HR, et al. Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol. 2007;6:29–38. doi: 10.1016/S1474-4422(06)70630-5. [DOI] [PubMed] [Google Scholar]
163.Maas AI, Murray GD. Magnesium for neuroprotection after traumatic brain injury. Lancet Neurol. 2007;6:20–21. doi: 10.1016/S1474-4422(06)70668-8. [DOI] [PubMed] [Google Scholar]
164.Heath DL, Vink R. Optimization of magnesium therapy after severe diffuse axonal brain injury in rats. J Pharmacol Exp Ther. 1999;288:1311–1316. [PubMed] [Google Scholar]
165.Aslanyan S, Weir CJ, Muir KW, Lees KR, IMAGES Study Investigators Magnesium for treatment of acute lacunar stroke syndromes: further analysis of the IMAGES trial. Stroke. 2007;38:1269–1273. doi: 10.1161/01.STR.0000259628.94421.09. [DOI] [PubMed] [Google Scholar]
166.Manet S, Marpeau L, Zupan-Simunek V, PREMAG Trial Group et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. BJOG. 2007;114:310–318. doi: 10.1111/j.1471-0528.2006.01162.x. [DOI] [PubMed] [Google Scholar]
167.Thal SC, Engelhard K, Werner C. New cerebral protection strategies. Curr Opin Anaesthesiol. 2005;18:490–495. doi: 10.1097/01.aco.0000182561.32680.30. [DOI] [PubMed] [Google Scholar]
168.Bhudia SK, Cosgrove DM, Naugle RI, et al. Magnesium as a neuroprotectant in cardiac surgery: a randomized clinical trial. J Thorac Cardiovasc Surg. 2006;131:853–861. doi: 10.1016/j.jtcvs.2005.11.018. [DOI] [PubMed] [Google Scholar]
169.Kaminska B, Gaweda-Walerych K, Zawadzka M. Molecular mechanisms of neuroprotective action of immunosuppressants: facts and hypotheses. J Cell Mol Med. 2004;8:45–48. doi: 10.1111/j.1582-4934.2004.tb00259.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
170.Riess P, Bareyre FM, Saatman KE, et al. Effects of chronic, post-injury cyclosporin A administration on motor and sensorimotor function following severe, experimental traumatic brain injury. Restor Neurol Neurosci. 2001;18:1–8. [PubMed] [Google Scholar]
171.Alessandri B, Rice AC, Levasseur J, DeFord M, Hamm RJ, Bullock RM. Cyclosporin A improves brain tissue oxygen consumption and learning/memory performance after lateral fluid percussion injury in rats. J Neurotrauma. 2002;19:829–841. doi: 10.1089/08977150260190429. [DOI] [PubMed] [Google Scholar]
172.Szabo I, Zoratti M. The giant channel of the inner mitochondrial membrane is inhibited by cyclosporin A. J Biol Chem. 1991;266:3376–3379. [PubMed] [Google Scholar]
173.Sullivan PG, Thompson MB, Scheff SW. Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. Exp Neurol. 1999;160:226–234. doi: 10.1006/exnr.1999.7197. [DOI] [PubMed] [Google Scholar]
174.Nakai A, Shibazaki Y, Taniuchi Y, Miyake H, Oya A, Takeshita T. Role of mitochondrial permeability transition in fetal brain damage in rats. Pediatr Neurol. 2004;30:247–253. doi: 10.1016/j.pediatrneurol.2003.09.006. [DOI] [PubMed] [Google Scholar]
175.Panickar KS, Jayakumar AR, Norenberg MD. Differential response of neural cells to trauma-induced free radical production in vitro. Neurochem Res. 2002;27:161–166. doi: 10.1023/a:1014875210852. [DOI] [PubMed] [Google Scholar]
176.Mirzayan MJ, Klinge PM, Ude S, et al. Modified calcium accumulation after controlled cortical impact under cyclosporin A treatment: a 45Ca autoradiographic study. Neurol Res. 2008;30:476–479. doi: 10.1179/174313208X276916. [DOI] [PubMed] [Google Scholar]
177.Uchino H, Ishii N, Shibasaki F. Calcineurin and cyclophilin D are differential targets of neuroprotection by immunosuppressants CsA and FK506 in ischemic brain damage. Acta Neurochir Suppl. 2003;86:105–111. doi: 10.1007/978-3-7091-0651-8_24. [DOI] [PubMed] [Google Scholar]
178.Mbye LH, Singh IN, Carrico KM, Saatman KE, Hall ED. Comparative neuroprotective effects of cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury. J Cereb Blood Flow Metab 2008 Aug. 20 [Epub ahead of print]. [DOI] [PMC free article] [PubMed]
179.Uchino H, Minamikawa-Tachino R, Kristian T, et al. Differential neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability transition. Neurobiol Dis. 2002;10:219–233. doi: 10.1006/nbdi.2002.0514. [DOI] [PubMed] [Google Scholar]
180.Domañska-Janik K, Buzañska L, Dłuzniewska J, Kozłowska H, Samowska A, Zabłocka B. Neuroprotection by cyclosporin A following transient brain ischemia correlates with the inhibition of the early efflux of cytochrome C to cytoplasm. Brain Res Mol Brain Res. 2004;121:50–59. doi: 10.1016/j.molbrainres.2003.11.006. [DOI] [PubMed] [Google Scholar]
181.Ferrand-Drake M, Zhu C, Gido G, et al. Cyclosporin A prevents calpain activation despite increased intracellular calcium concentrations, as well as translocation of apoptosis-inducing factor, cytochrome c and caspase-3 activation in neurons exposed to transient hypoglycemia. J Neurochem. 2003;85:1431–1442. doi: 10.1046/j.1471-4159.2003.01794.x. [DOI] [PubMed] [Google Scholar]
182.Santos JB, Schauwecker PE. Protection provided by cyclosporin A against excitotoxic neuronal death is genotype specific. Epilepsia. 2003;44:995–1002. doi: 10.1046/j.1528-1157.2003.66302.x. [DOI] [PubMed] [Google Scholar]
183.Van Den Heuvel C, Donkin JJ, Finnic JW, et al. Downregulation of amyloid precursor protein (APP) expression following post-traumatic cyclosporin-A administration. J Neurotrauma. 2004;21:1562–1572. doi: 10.1089/neu.2004.21.1562. [DOI] [PubMed] [Google Scholar]
184.Okonkwo DO, Melon DE, Pellicane AJ, et al. Dose-response of cyclosporin A in attenuating traumatic axonal injury in rat. Neuro Report. 2003;14:463–466. doi: 10.1097/00001756-200303030-00033. [DOI] [PubMed] [Google Scholar]
185.Buki A, Okonkwo DO, Povlishock JT. Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury. J Neurotrauma. 1999;16:511–521. doi: 10.1089/neu.1999.16.511. [DOI] [PubMed] [Google Scholar]
186.Okonkwo DO, Povlishock JT. An intrathecal bolus of cyclosporin A before injury preserves mitochondrial integrity and attenuates axonal disruption in traumatic brain injury. J Cereb Blood Flow Metab. 1999;19:443–451. doi: 10.1097/00004647-199904000-00010. [DOI] [PubMed] [Google Scholar]
187.Okonkwo DO, Buki A, Siman R, Povlishock JT. Cyclosporin A limits calcium-induced axonal damage following traumatic brain injury. NeuroReport. 1999;10:353–358. doi: 10.1097/00001756-199902050-00026. [DOI] [PubMed] [Google Scholar]
188.Suehiro E, Singleton RH, Stone JR, Povlishock JT. The immunophilin ligand FK506 attenuated the axonal damage associated with rapid rewarming following posttraumatic hypothermia. Exp Neurol. 2001;172:199–210. doi: 10.1006/exnr.2001.7765. [DOI] [PubMed] [Google Scholar]
189.Empey PE, McNamara PJ, Young B, Rosbolt MB, Hatton J. Cyclosporin A disposition following acute traumatic brain injury. J Neurotrauma. 2006;23:109–116. doi: 10.1089/neu.2006.23.109. [DOI] [PubMed] [Google Scholar]
190.Mazzeo AT, Alves OL, Gilman CB, et al. Brain metabolic and hemodynamic effects of cyclosporin A after human severe traumatic brain injury: a microdialysis study. Acta Neurochir (Wien) 2008;150:1019–1031. doi: 10.1007/s00701-008-0021-7. [DOI] [PubMed] [Google Scholar]
191.Faden AI. Role of thyrotropin-releasing hormone and opiate receptor antagonists in limiting central nervous system injury. Adv Neurol. 1988;47:531–546. [PubMed] [Google Scholar]
192.McIntosh TK, Vink R, Faden AI. An analog of thyrotropin-releasing hormone improves outcome after traumatic brain injury: 31P NMR studies. Am J Physiol. 1988;254:R785–R792. doi: 10.1152/ajpregu.1988.254.5.R785. [DOI] [PubMed] [Google Scholar]
193.Vink R, McIntosh TK, Faden AI. Treatment with the thyrotropin-releasing hormone analog CG3703 restores magnesium homeostasis following traumatic brain injury in rats. Brain Res. 1988;460:184–188. doi: 10.1016/0006-8993(88)91221-8. [DOI] [PubMed] [Google Scholar]
194.Dewitt DS, Rough DS, Uchida T, Deal DD, Vines SM. Effects of nalmefene, CG3703, tirilazad, or dopamine on cerebral blood flow, oxygen delivery, and electroencephalographic activity after traumatic brain injury and hemorrhage. J Neurotrauma. 1997;14:931–941. doi: 10.1089/neu.1997.14.931. [DOI] [PubMed] [Google Scholar]
195.Maejima S, Katayama Y. Neurosurgical trauma in Japan. World J Surg. 2001;25:1205–1209. doi: 10.1007/s00268-001-0083-7. [DOI] [PubMed] [Google Scholar]
196.Faden AI, Fox GB, Fan L, et al. Novel TRH analog improves motor and cognitive recovery after traumatic brain injury in rodents. Am J Physiol. 1999;277:R1196–R1204. doi: 10.1152/ajpregu.1999.277.4.R1196. [DOI] [PubMed] [Google Scholar]
197.Faden AI, Movsesyan VA, Knoblach SM, Ahmed F, Cernak I. Neuroprotective effects of novel small peptides in vitro and after brain injury. Neuropharmacology. 2005;49:410–424. doi: 10.1016/j.neuropharm.2005.04.001. [DOI] [PubMed] [Google Scholar]
198.Niu GM, Gu XJ, Su YL, Wan F, Su FZ, Xue DL. Effect of thyrotropin-releasing hormone on cerebral free radical reactions following acute brain injury in rabbits. Chin J Traumatol. 2003;6:104–106. [PubMed] [Google Scholar]

[CR1] 1.Finfer SR, Cohen J. Severe traumatic brain injury. Resuscitation. 2001;48:77–90. doi: 10.1016/s0300-9572(00)00321-x. [DOI] [PubMed] [Google Scholar]

[CR2] 2.Kraus JF. Epidemiology of head injury. In: Cooper PR, editor. Head injury. 3rd ed. Baltimore: Williams & Wilkins; 1993. pp. 1–25. [Google Scholar]

[CR3] 3.Hillier SL, Hiller JE, Metzer J. Epidemiology of traumatic brain injury in South Australia. Brain Injury. 1997;11:649–659. doi: 10.1080/026990597123205. [DOI] [PubMed] [Google Scholar]

[CR4] 4.Mendelow AD, Crawford PJ. Primary and secondary brain injury. In: Reilly PL, Bullock R, editors. Head injury: pathophysiology and management of severe closed injury. 1st ed. London: Chapman & Hall; 1997. pp. 72–88. [Google Scholar]

[CR5] 5.McIntosh TK, Smith DH, Meaney DF, Kotapka MJ, Gennarelli TA, Graham DI. Neuropathological sequelae of traumatic brain injury: relationship to neurochemical and biomechanical mechanisms. Lab Invest. 1996;74:315–342. [PubMed] [Google Scholar]

[CR6] 6.Maas AI. Neuroprotective agents in traumatic brain injury. Expert Opin Investig Drugs. 2001;10:753–767. doi: 10.1517/13543784.10.4.753. [DOI] [PubMed] [Google Scholar]

[CR7] 7.Narayan RK, Michel ME, Ansell B, et al. Clinical Trials in Head Injury Study Group. J Neurotrauma. 2002;19:503–557. doi: 10.1089/089771502753754037. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR8] 8.Tolias CM, Bullock MR. Critical appraisal of neuroprotection trials in head injury: what have we learned? NeuroRx. 2004;1:71–79. doi: 10.1602/neurorx.1.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR9] 9.Faden AI. Neuroprotection and traumatic brain injury: theoretical option or realistic proposition? Curr Opin Neurol. 2002;15:707–712. doi: 10.1097/01.wco.0000044767.39452.bf. [DOI] [PubMed] [Google Scholar]

[CR10] 10.Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244:1360–1362. doi: 10.1126/science.2660263. [DOI] [PubMed] [Google Scholar]

[CR11] 11.Hickenbottom SL, Grotta J. Neuroprotective therapy. Semin Neurol. 1998;18:485–492. doi: 10.1055/s-2008-1040901. [DOI] [PubMed] [Google Scholar]

[CR12] 12.Gentile NT, McIntosh TK. Antagonists of excitatory amino acids and endogenous opioid peptides in the treatment of experimental central nervous systems injury. Ann Emerg Med. 1993;22:1028–1035. doi: 10.1016/s0196-0644(05)82746-5. [DOI] [PubMed] [Google Scholar]

[CR13] 13.Willis C, Lybrand S, Bellamy N. Excitatory amino acid inhibitors for traumatic brain injury. Cochrane Database Syst Rev. 2004; (l):CD003986. [DOI] [PMC free article] [PubMed]

[CR14] 14.Faden AI, Demediuk P, Panter SS, Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science. 1989;244:798–800. doi: 10.1126/science.2567056. [DOI] [PubMed] [Google Scholar]

[CR15] 15.Lea PM, Faden AI. Traumatic brain injury: developmental differences in glutamate receptor response and the impact on treatment. Ment Retard Dev Disabil Res Rev. 2001;7:235–248. doi: 10.1002/mrdd.1033. [DOI] [PubMed] [Google Scholar]

[CR16] 16.Haeberlein SL. Mitochondrial function in apoptotic neuronal cell death. Neurochem Res. 2004;29:521–530. doi: 10.1023/b:nere.0000014823.74782.b7. [DOI] [PubMed] [Google Scholar]

[CR17] 17.Signoretti S, Marmarou A, Aygok GA, Fatouros PP, Portella G, Bullock RM. Assessment of mitochondrial impairment in traumatic brain injury using high-resolution proton magnetic resonance spectroscopy. J Neurosurg. 2008;108:42–52. doi: 10.3171/JNS/2008/108/01/0042. [DOI] [PubMed] [Google Scholar]

[CR18] 18.Petronilli V, Penzo D, Scorrano L, Bemardi P, Di Lisa F. The mitochondrial permeability transition, release of cytochrome c and cell death: correlation with the duration of pore openings in situ. J Biol Chem. 2001;276:12030–12034. doi: 10.1074/jbc.M010604200. [DOI] [PubMed] [Google Scholar]

[CR19] 19.Hansson MJ, Månsson R, Mattiasson G, et al. Brain-derived respiring mitochondria exhibit homogeneous, complete and cyclosporin-sensitive permeability transition. J Neurochem. 2004;89:715–729. doi: 10.1111/j.1471-4159.2004.02400.x. [DOI] [PubMed] [Google Scholar]

[CR20] 20.Fiskum G. Mitochondrial participation in ischemic and traumatic neural cell death. J Neurotrauma. 2000;17:843–855. doi: 10.1089/neu.2000.17.843. [DOI] [PubMed] [Google Scholar]

[CR21] 21.Fiskum G. Mechanisms of neuronal death and neuroprotection. J Neurosurg Anesthesiol. 2004;16:108–110. doi: 10.1097/00008506-200401000-00025. [DOI] [PubMed] [Google Scholar]

[CR22] 22.Mattiasson G, Friberg H, Hansson M, Elmér E, Wieloch T. Flow cytometric analysis of mitochondria from CA1 and CA3 regions of rat hippocampus reveals differences in permeability transition pore activation. J Neurochem. 2003;87:532–544. doi: 10.1046/j.1471-4159.2003.02026.x. [DOI] [PubMed] [Google Scholar]

[CR23] 23.Lemasters JJ, Nieminen AL, Qian T, et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta. 1998;1366:177–196. doi: 10.1016/s0005-2728(98)00112-1. [DOI] [PubMed] [Google Scholar]

[CR24] 24.Xiong Y, Gu Q, Peterson PL, Muizelaar JP, Lee CP. Mitochondrial dysfunction and calcium pertubation induced by traumatic brain injury. J Neurotrauma. 1997;14:23–34. doi: 10.1089/neu.1997.14.23. [DOI] [PubMed] [Google Scholar]

[CR25] 25.Clausen T, Zauner A, Levasseur JE, Rice AC, Bullock R. Induced mitochondrial failure in the feline brain: implications for understanding acute post-traumatic metabolic events. Brain Res. 2001;908:35–48. doi: 10.1016/s0006-8993(01)02566-5. [DOI] [PubMed] [Google Scholar]

[CR26] 26.Cernak I, Savic VJ, Kotur J, Prokic V, Veljovic M, Grbovic D. Characterization of plasma magnesium concentration and oxidative stress following graded traumatic brain injury in humans. J Neurotrauma. 2000;17:53–68. doi: 10.1089/neu.2000.17.53. [DOI] [PubMed] [Google Scholar]

[CR27] 27.Ikeda Y, Long DM. The molecular basis of brain injury and brain edema: the role of oxygen free radicals. Neurosurgery. 1990;27:1–11. doi: 10.1097/00006123-199007000-00001. [DOI] [PubMed] [Google Scholar]

[CR28] 28.Lewén A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma. 2000;17:871–890. doi: 10.1089/neu.2000.17.871. [DOI] [PubMed] [Google Scholar]

[CR29] 29.Shohami E, Beit-Yannai E, Horowitz M, Kohen R. Oxidative stress in closed-head injury: brain antioxidant capacity as an indicator of functional outcome. J Cereb Blood Flow Metab. 1997;17:1007–1019. doi: 10.1097/00004647-199710000-00002. [DOI] [PubMed] [Google Scholar]

[CR30] 30.Hall ED, Yonkers PA, Andrus PK, Cox JW, Anderson DK. Biochemistry and pharmacology of lipid antioxidants in acute brain and spinal cord injury. J Neurotrauma. 1992;9:S425–S442. [PubMed] [Google Scholar]

[CR31] 31.Marklund N, Clausen F, Lewander T, Hillered L. Monitoring of reactive oxygen species production after traumatic brain injury in rats with microdialysis and the 4-hydroxybenzoic acid trapping method. J Neurotrauma. 2001;18:1217–1227. doi: 10.1089/089771501317095250. [DOI] [PubMed] [Google Scholar]

[CR32] 32.Morganti-Kossmann MC, Satgunaseelan L, Bye N, Kossmann T. Modulation of immune response by head injury. Injury. 2007;38:1360–1362. doi: 10.1016/j.injury.2007.10.005. [DOI] [PubMed] [Google Scholar]

[CR33] 33.Israelsson C, Bengtsson H, Kylberg A, et al. Distinct cellular patterns of upregulated chemokine expression supporting a prominent inflammatory role in traumatic brain injury. J Neurotrauma. 2008;25:959–974. doi: 10.1089/neu.2008.0562. [DOI] [PubMed] [Google Scholar]

[CR34] 34.Craft JM, Watterson DM, Van Eldik LJ. Neuroinflammation: a potential therapeutic target. Expert Opin Ther Targets. 2005;9:887–900. doi: 10.1517/14728222.9.5.887. [DOI] [PubMed] [Google Scholar]

[CR35] 35.Habgood MD, Bye N, Dziegielewska KM, et al. Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice. Eur J Neurosci. 2007;25:231–238. doi: 10.1111/j.1460-9568.2006.05275.x. [DOI] [PubMed] [Google Scholar]

[CR36] 36.Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16:1–13. doi: 10.1016/j.nbd.2003.12.016. [DOI] [PubMed] [Google Scholar]

[CR37] 37.Nimmo AJ, Cernak I, Heath DL, Hu X, Bennett CJ, Vink R. Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. Neuropeptides. 2004;38:40–47. doi: 10.1016/j.npep.2003.12.003. [DOI] [PubMed] [Google Scholar]

[CR38] 38.Krizanac-Bengez L, Mayberg MR, Janigro D. The cerebral vasculature as a therapeutic target for neurological disorders and the role of shear stress in vascular homeostatis [sic] and pathophysiology. Neurol Res. 2004;26:846–853. doi: 10.1179/016164104X3789. [DOI] [PubMed] [Google Scholar]

[CR39] 39.Klatzo I. Brain Edema. In: Odom GL, editor. Central nervous system trauma research status report. Washington, DC: National Institutes of Health; 1979. pp. 110–112. [Google Scholar]

[CR40] 40.Baskaya MK, Dogan A, Rao AM, Dempsey RJ. Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. J Neurosurg. 2000;92:448–452. doi: 10.3171/jns.2000.92.3.0448. [DOI] [PubMed] [Google Scholar]

[CR41] 41.Kimelberg HK. Current concepts of brain edema: review of laboratory investigations. J Neurosurg. 1995;83:1051–1059. doi: 10.3171/jns.1995.83.6.1051. [DOI] [PubMed] [Google Scholar]

[CR42] 42.Stover JF, Unterberg AW. Increased cerebrospinal fluid glutamate and taurine concentrations are associated with traumatic brain edema formation in rats. Brain Res. 2000;875:51–55. doi: 10.1016/s0006-8993(00)02597-x. [DOI] [PubMed] [Google Scholar]

[CR43] 43.Duvdevani R, Roof RL, Fulop Z, Hoffman SW, Stein DG. Blood-brain barrier breakdown and edema formation following frontal cortical contusion: does hormonal status play a role? J Neurotrauma. 1995;12:65–75. doi: 10.1089/neu.1995.12.65. [DOI] [PubMed] [Google Scholar]

[CR44] 44.Graham DI. Neuropathology of head injury. In: Narayan RK, Wilberger JE, Povlishock JT, editors. Neurotrauma. New York: McGraw-Hill; 1996. [Google Scholar]

[CR45] 45.Treggiari MM, Schutz N, Yanez ND, Romand JA. Role of intracranial pressure values and patterns in predicting outcome in traumatic brain injury: a systematic review. Neurocrit Care. 2007;6:104–112. doi: 10.1007/s12028-007-0012-1. [DOI] [PubMed] [Google Scholar]

[CR46] 46.Carter BG, Butt W, Taylor A. ICP and CPP: excellent predictors of long term outcome in severely brain injured children. Childs Nerv Syst. 2008;24:245–251. doi: 10.1007/s00381-007-0461-z. [DOI] [PubMed] [Google Scholar]

[CR47] 47.Walberer M, Ritschel N, Nedelmann M, et al. Aggravation of infarct formation by brain swelling in a large territorial stroke: a target for neuroprotection? J Neurosurg. 2008;109:287–293. doi: 10.3171/JNS/2008/109/8/0287. [DOI] [PubMed] [Google Scholar]

[CR48] 48.Reilly PL. Management of intracranial pressure and cerebral perfusion. In: Reilly PL, Bullock R, editors. Head injury: pathophysiology and management of severe closed injury. 1st ed. London: Chapman & Hall; 1997. pp. 385–406. [Google Scholar]

[CR49] 49.Reiss AB, Wirkowski E. Role of HMG-CoA reductase inhibitors in neurological disorders: progress to date. Drugs. 2007;67:2111–2120. doi: 10.2165/00003495-200767150-00001. [DOI] [PubMed] [Google Scholar]

[CR50] 50.Rajanikant GK, Zemke D, Kassab M, Majid A. The therapeutic potential of statins in neurological disorders. Curr Med Chem. 2007;14:103–112. doi: 10.2174/092986707779313462. [DOI] [PubMed] [Google Scholar]

[CR51] 51.Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/ Rho-kinase and Akt pathways. Circulation. 2002;105:1756–1759. doi: 10.1161/01.cir.0000015465.73933.3b. [DOI] [PubMed] [Google Scholar]

[CR52] 52.Maeda T, Kawane T, Horiuchi N. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology. 2003;144:681–692. doi: 10.1210/en.2002-220682. [DOI] [PubMed] [Google Scholar]

[CR53] 53.Delanty N, Vaughan CJ, Sheehy N. Statins and neuroprotection. Expert Opin Investig Drugs. 2001;10:1847–1853. doi: 10.1517/13543784.10.10.1847. [DOI] [PubMed] [Google Scholar]

[CR54] 54.Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol. 2003;58:719–731. doi: 10.1007/s00228-002-0556-0. [DOI] [PubMed] [Google Scholar]

[CR55] 55.Zacco A, Togo J, Spence K, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci. 2003;23:11104–11111. doi: 10.1523/JNEUROSCI.23-35-11104.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR56] 56.Bösel J, Gandor F, Harms C, et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem. 2005;92:1386–1398. doi: 10.1111/j.1471-4159.2004.02980.x. [DOI] [PubMed] [Google Scholar]

[CR57] 57.Dolga AM, Nijholt IM, Ostroveanu A, Ten Bosch Q, Luiten PG, Eisel UL. Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J Alzheimers Dis. 2008;13:111–122. doi: 10.3233/jad-2008-13201. [DOI] [PubMed] [Google Scholar]

[CR58] 58.Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53:743–751. doi: 10.1002/ana.10555. [DOI] [PubMed] [Google Scholar]

[CR59] 59.Lu D, Mahmood A, Goussev A, et al. Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury. J Neurosurg. 2004;101:813–821. doi: 10.3171/jns.2004.101.5.0813. [DOI] [PubMed] [Google Scholar]

[CR60] 60.Lu D, Qu C, Goussev A, et al. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma. 2007;24:1132–1146. doi: 10.1089/neu.2007.0288. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR61] 61.Franke C, Noldner M, Abdel-Kader R, et al. Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiol Dis. 2007;25:438–445. doi: 10.1016/j.nbd.2006.10.004. [DOI] [PubMed] [Google Scholar]

[CR62] 62.Pannu R, Christic DK, Barbosa E, Singh I, Singh AK. Posttrauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury. J Neurochem. 2007;101:182–200. doi: 10.1111/j.1471-4159.2006.04354.x. [DOI] [PubMed] [Google Scholar]

[CR63] 63.Cimino M, Gelosa P, Gianella A, Nobili E, Tremoli E, Sironi L. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist. 2007;13:208–213. doi: 10.1177/1073858406297121. [DOI] [PubMed] [Google Scholar]

[CR64] 64.Paintlia AS, Paintlia MK, Singh I, Skoff RB, Singh AK. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia 2008 Aug. 20 [Epub ahead of print]. [DOI] [PMC free article] [PubMed]

[CR65] 65.Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 1999;22:410–416. doi: 10.1016/s0166-2236(99)01399-5. [DOI] [PubMed] [Google Scholar]

[CR66] 66.Komeyev A, Costa E. Allopregnanolone (THP) mediates anesthetic effects of progesterone in rat brain. Horm Behav. 1996;30:37–43. doi: 10.1006/hbeh.1996.0006. [DOI] [PubMed] [Google Scholar]

[CR67] 67.Rodgers RJ, Johnson NJ. Behaviorally selective effects of neuroactive steroids on plus-maze anxiety in mice. Pharmacol Biochem Behav. 1998;59:221–232. doi: 10.1016/s0091-3057(97)00339-0. [DOI] [PubMed] [Google Scholar]

[CR68] 68.Frye CA, Walf AA, Rhodes ME, Hamey JP. Progesterone enhances motor, anxiolytic, analgesic, and antidepressive behavior of wild-type mice, but not those deficient in type 1 5α-reductase. Brain Res. 2004;1004:116–124. doi: 10.1016/j.brainres.2004.01.020. [DOI] [PubMed] [Google Scholar]

[CR69] 69.Gonzalez Deniselle MC, Costa JJL, Gonzalez SL, et al. Basis of progesterone protection in spinal cord neurodegeneration. J Steroid Biochem Mol Biol. 2002;83:199–209. doi: 10.1016/s0960-0760(02)00262-5. [DOI] [PubMed] [Google Scholar]

[CR70] 70.Kumon Y, Soon CK, Tompkins P, Stevens Al, Sakaki S, Loftus M. Neuroprotective effect of postischemic administration of progesterone in spontaneously hypertensive rats with focal cerebral ischemia. J Neurosurg. 2000;92:848–852. doi: 10.3171/jns.2000.92.5.0848. [DOI] [PubMed] [Google Scholar]

[CR71] 71.Jiang N, Chopp M, Stein D, Feit H. Progesterone is neuroprotective after transient middle cerebral occlusion in male rats. Brain Res. 1996;735:101–107. doi: 10.1016/0006-8993(96)00605-1. [DOI] [PubMed] [Google Scholar]

[CR72] 72.Vongher J, Frye C. Progesterone in conjunction with estradiol has neuroprotective effects in an animal model of neurodegeneration. Pharmacol Biochem Behav. 1999;64:777–785. doi: 10.1016/s0091-3057(99)00140-9. [DOI] [PubMed] [Google Scholar]

[CR73] 73.Roof RL, Hall ED. Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. J Neurotrauma. 2000;17:367–388. doi: 10.1089/neu.2000.17.367. [DOI] [PubMed] [Google Scholar]

[CR74] 74.Ogata T, Nakamura Y, Tsuji K, Shibata T, Kataoka K. Steroid hormones protect spinal cord neurons from glutamate toxicity. Neuroscience. 1993;55:445–449. doi: 10.1016/0306-4522(93)90513-f. [DOI] [PubMed] [Google Scholar]

[CR75] 75.Paul SM, Purdy RH. Neuroactive steroids. FASEB J. 1992;6:2311–2322. [PubMed] [Google Scholar]

[CR76] 76.Thomas AJ, Nockles RP, Hiu QP, Shaffrey CI, Chopp M. Progesterone is neuroprotective after acute experimental spinal cord trauma in rats. Spine. 1999;24:2134–2138. doi: 10.1097/00007632-199910150-00013. [DOI] [PubMed] [Google Scholar]

[CR77] 77.Labombarda F, Gonzalez SL, Gonzalez Deniselle MC, Guennoun R, Schumacher M, de Nicola AF. Cellular basis for progesterone neuroprotection in the injured spinal cord. J Neurotrauma. 2002;19:343–355. doi: 10.1089/089771502753594918. [DOI] [PubMed] [Google Scholar]

[CR78] 78.Gonzalez-Vidal MD, Cervera-Gaviria M, Ruelas R, Escobar A, Moralí G, Cervantes M. Progesterone: protective effects on the cat hippocampal neuronal damage due to acute global cerebral ischemia. Arch Med Res. 1998;28:117–124. [PubMed] [Google Scholar]

[CR79] 79.Koenig HL, Gong WH, Pelissier P. Role of progesterone in peripheral nerve repair. Rev Reprod. 2000;5:189–199. doi: 10.1530/ror.0.0050189. [DOI] [PubMed] [Google Scholar]

[CR80] 80.Gruber CJ, Huber JC. Differential effects of progestins on the brain. Maturitas. 2003;46(Suppl 1):S71–S75. doi: 10.1016/j.maturitas.2003.09.021. [DOI] [PubMed] [Google Scholar]

[CR81] 81.Roof RL, Zhang Q, Glasier MM, Stein DG. Gender-specific impairment on Morris water maze task after entorhinal cortex lesion. Behav Brain Res. 1993;57:47–51. doi: 10.1016/0166-4328(93)90060-4. [DOI] [PubMed] [Google Scholar]

[CR82] 82.Roof RL, Duvdevani R, Braswell L, Stein DG. Progesterone facilitates cognitive recovery and reduces secondary neuronal loss caused by cortical contusion injury in male rats. Exp Neurol. 1994;129:64–69. doi: 10.1006/exnr.1994.1147. [DOI] [PubMed] [Google Scholar]

[CR83] 83.Shear DA, Galani R, Hoffman SW, Stein DG. Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp Neurol. 2002;178:59–67. doi: 10.1006/exnr.2002.8020. [DOI] [PubMed] [Google Scholar]

[CR84] 84.He J, Hoffman SW, Stein DG. Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury. Restor Neurol Neurosci. 2004;22:19–31. [PubMed] [Google Scholar]

[CR85] 85.Roof RL, Hoffman SW, Stein DG. Progesterone protects against lipid peroxidation following traumatic brain injury in rats. Mol Chem Neuropathol. 1997;31:1–11. doi: 10.1007/BF02815156. [DOI] [PubMed] [Google Scholar]

[CR86] 86.Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurones. J Neurochem. 1996;66:1836–1844. doi: 10.1046/j.1471-4159.1996.66051836.x. [DOI] [PubMed] [Google Scholar]

[CR87] 87.Smith SS. Progesterone administration attenuates excitatory amino acid responses of cerebellar Purkinje cells. Neuroscience. 1991;42:309–320. doi: 10.1016/0306-4522(91)90377-z. [DOI] [PubMed] [Google Scholar]

[CR88] 88.Cai W, Zhu Y, Furuya K, Li Z, Sokabe M, Chen L. Two different molecular mechanisms underlying progesterone neuroprotection against ischemic brain damage. Neuropharmacology. 2008;55:127–138. doi: 10.1016/j.neuropharm.2008.04.023. [DOI] [PubMed] [Google Scholar]

[CR89] 89.Djebaili M, Hoffman SW, Stein DG. Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. Neuroscience. 2004;123:349–359. doi: 10.1016/j.neuroscience.2003.09.023. [DOI] [PubMed] [Google Scholar]

[CR90] 90.O’Connor CA, Cernak I, Johnson F, Vink R. Effects of progesterone on neurologic and morphologic outcome following diffuse traumatic brain injury in rats. Exp Neurol. 2007;205:145–153. doi: 10.1016/j.expneurol.2007.01.034. [DOI] [PubMed] [Google Scholar]

[CR91] 91.Pettus EH, Wright DW, Stein DG, Hoffman SW. Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. Brain Res. 2005;1049:112–119. doi: 10.1016/j.brainres.2005.05.004. [DOI] [PubMed] [Google Scholar]

[CR92] 92.Roof RL, Duvdevani R, Stein DG. Progesterone treatment attenuates brain edema following contusion injury in male and female rats. Restor Neurol Neurosci. 1992;4:425–427. doi: 10.3233/RNN-1992-4608. [DOI] [PubMed] [Google Scholar]

[CR93] 93.O’Connor CA, Cernak I, Vink R. Both estrogen and progesterone attenuate edema formation following diffuse traumatic brain injury in rats. Brain Res. 2005;1062:171–174. doi: 10.1016/j.brainres.2005.09.011. [DOI] [PubMed] [Google Scholar]

[CR94] 94.Roof RL, Duvdevani R, Heybum JW, Stein DG. Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective. Exp Neurol. 1996;138:246–251. doi: 10.1006/exnr.1996.0063. [DOI] [PubMed] [Google Scholar]

[CR95] 95.Wright DW, Bauer ME, Hoffman SW, Stein DG. Serum progesterone levels correlate with decreased cerebral edema after traumatic brain injury in male rats. J Neurotrauma. 2001;18:901–909. doi: 10.1089/089771501750451820. [DOI] [PubMed] [Google Scholar]

[CR96] 96.Limmroth V, Lee WS, Moskowitz MA. GABAA-receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges. Br J Pharmacol. 1996;117:99–104. doi: 10.1111/j.1476-5381.1996.tb15160.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR97] 97.Kuebler JF, Yokoyama Y, Jarrar D, et al. Administration of progesterone after trauma and hemorrhagic shock prevents hepatocellular injury. Arch Surg. 2003;138:727–734. doi: 10.1001/archsurg.138.7.727. [DOI] [PubMed] [Google Scholar]

[CR98] 98.Kuebler JF, Jarrar D, Bland KI, Rue L, Wang P, Chaudry IH. Progesterone administration after trauma and hemorrhagic shock improves cardiovascular responses. Crit Care Med. 2003;31:1786–1793. doi: 10.1097/01.CCM.0000063441.41446.23. [DOI] [PubMed] [Google Scholar]

[CR99] 99.Wright DW, Kellermann AL, Hertzberg VS, et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med. 2007;49:391–402. doi: 10.1016/j.annemergmed.2006.07.932. [DOI] [PubMed] [Google Scholar]

[CR100] 100.Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care. 2008;12:R61–R61. doi: 10.1186/cc6887. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR101] 101.Lapchak PA. Carbamylated erythropoietin to treat neuronal injury: new development strategies. Expert Opin Investig Drugs. 2008;17:1175–1186. doi: 10.1517/13543784.17.8.1175. [DOI] [PubMed] [Google Scholar]

[CR102] 102.Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A. 2000;97:10526–10531. doi: 10.1073/pnas.97.19.10526. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR103] 103.Grasso G, Sfacteria A, Meli F, Fodale V, Buemi M, Iacopino DG. Neuroprotection by erythropoietin administration after experimental traumatic brain injury. Brain Res. 2007;1182:99–105. doi: 10.1016/j.brainres.2007.08.078. [DOI] [PubMed] [Google Scholar]

[CR104] 104.Cherian L, Goodman JC, Robertson C. Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats. J Pharmacol Exp Ther. 2007;322:789–794. doi: 10.1124/jpet.107.119628. [DOI] [PubMed] [Google Scholar]

[CR105] 105.Elfar JC, Jacobson JA, Puzas JE, Rosier RN, Zuscik MJ. Erythropoietin accelerates functional recovery after peripheral nerve injury. J Bone Joint Surg Am. 2008;90:1644–1653. doi: 10.2106/JBJS.G.00557. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR106] 106.Xiong Y, Lu D, Qu C, et al. Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice. J Neurosurg. 2008;109:510–521. doi: 10.3171/JNS/2008/109/9/0510. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR107] 107.Yuan RR, Li WP, Menonna J, Maeda Y, Dowling PC. Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators 2007: International Application Number PCT/ 1B2006/003581. Patent Publication Number WO2007052154 (A2). Available at: http://v3.espacenet.com/publicationDetails/biblio? KC=A2&date=20070510&NR=2007052154A2&DB=EPODOC&locale=en_EP&CC=WO&FT=D.

[CR108] 108.King CE, Rodger J, Bartlett C, Esmaili T, Dunlop SA, Beazley LD. Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection. Exp Neurol. 2007;205:48–55. doi: 10.1016/j.expneurol.2007.01.017. [DOI] [PubMed] [Google Scholar]

[CR109] 109.Xiong Y, Mahmood A, Lu D, et al. Histological and functional outcomes after traumatic brain injury in mice null for the erythropoietin receptor in the central nervous system. Brain Res. 2008;1230:247–257. doi: 10.1016/j.brainres.2008.06.127. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR110] 110.Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem. 2005;94:819–827. doi: 10.1111/j.1471-4159.2005.03219.x. [DOI] [PubMed] [Google Scholar]

[CR111] 111.Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery. 2001;48:1393–1399. doi: 10.1097/00006123-200106000-00051. [DOI] [PubMed] [Google Scholar]

[CR112] 112.Wells JE, Huribert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain. 2003;126:1628–1637. doi: 10.1093/brain/awg178. [DOI] [PubMed] [Google Scholar]

[CR113] 113.Teng YD, Choi H, Onario RC, et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A. 2004;101:3071–3076. doi: 10.1073/pnas.0306239101. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR114] 114.Yune TY, Lee JY, Jung GY, et al. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J Neurosci. 2007;27:7751–7761. doi: 10.1523/JNEUROSCI.1661-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR115] 115.Fan LW, Pang Y, Lin S, et al. Minocycline reduces lipopolysaccharide-induced neurological dysfunction and brain injury in the neonatal rat. J Neurosci Res. 2005;82:71–82. doi: 10.1002/jnr.20623. [DOI] [PubMed] [Google Scholar]

[CR116] 116.Bye N, Habgood MD, Callaway JK, et al. Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. Exp Neurol. 2007;204:220–233. doi: 10.1016/j.expneurol.2006.10.013. [DOI] [PubMed] [Google Scholar]

[CR117] 117.Carty ML, Wixey JA, Colditz PB, Buller KM. Post-insult minocycline treatment attenuates hypoxia-ischemia-induced neuroinflammation and white matter injury in the neonatal rat: a comparison of two different dose regimens. Int J Dev Neurosci. 2008;26:477–485. doi: 10.1016/j.ijdevneu.2008.02.005. [DOI] [PubMed] [Google Scholar]

[CR118] 118.Chung KF. Drugs to suppress cough. Expert Opin Investig Drugs. 2005;14:19–27. doi: 10.1517/13543784.14.1.19. [DOI] [PubMed] [Google Scholar]

[CR119] 119.Rodi D, Couture R, Ongali B, Simonato M. Targeting kinin receptors for the treatment of neurological diseases. Curr Pharm Des. 2005;11:1313–1326. doi: 10.2174/1381612053507422. [DOI] [PubMed] [Google Scholar]

[CR120] 120.Noda M, Kariura Y, Pannasch U, et al. Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia. J Neurochem. 2007;101:397–410. doi: 10.1111/j.1471-4159.2006.04339.x. [DOI] [PubMed] [Google Scholar]

[CR121] 121.Kaplanski J, Pruneau D, Asa I, et al. LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats. J Neurotrauma. 2002;19:953–964. doi: 10.1089/089771502320317104. [DOI] [PubMed] [Google Scholar]

[CR122] 122.Marmarou A, Nichols J, Burgess J, et al. American Brain Injury Consortium Study Group. Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. J Neurotrauma. 1999;16:431–444. doi: 10.1089/neu.1999.16.431. [DOI] [PubMed] [Google Scholar]

[CR123] 123.Maggi CA. Pharmacology of the efferent function of primary sensory neurons. In: Geppetti P, Holzer P, editors. Neurogenic inflammation. Boca Raton, FL: CRC Press; 1996. [Google Scholar]

[CR124] 124.Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998;281:1640–1645. doi: 10.1126/science.281.5383.1640. [DOI] [PubMed] [Google Scholar]

[CR125] 125.Nessler S, Stadelmann C, Bittner A, et al. Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist: a putative role for substance P in CNS inflammation. J Neuroimmunol. 2006;179:1–8. doi: 10.1016/j.jneuroim.2006.06.026. [DOI] [PubMed] [Google Scholar]

[CR126] 126.Reardon K, Heath DL, Nimmo AJ, Vink R, Whitfield K. Inhibition of neurogenic inflammation attenuates the inflammatory response following traumatic brain injury in rats. In: 7th International Neurotrauma Symposium. Bologna: Medimond International Proceedings, 2004:115–118.

[CR127] 127.Donkin JJ, Turner RJ, Hassan I, Vink R. Substance P in traumatic brain injury. Prog Brain Res. 2007;161:97–109. doi: 10.1016/S0079-6123(06)61007-8. [DOI] [PubMed] [Google Scholar]

[CR128] 128.Alvaro G, Di Fabio R. Neurokinin 1 receptor antagonists: current prospects. Curr Opin Drug Discov Devel. 2007;10:613–621. [PubMed] [Google Scholar]

[CR129] 129.Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675–680. doi: 10.1038/90609. [DOI] [PubMed] [Google Scholar]

[CR130] 130.Marsh BJ, Stenzel-Poore MP. Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases. Curr Opin Pharmacol. 2008;8:8–13. doi: 10.1016/j.coph.2007.09.009. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR131] 131.Van Noort JM, Bsibsi M. Use of TLR3 agonists for treatment of neurodegenerative disorders 2007, Patent Application Number WO2007089151 [Available at: http://www.wipo.int/pctdb/en/wo. jsp?wo=2007089151].

[CR132] 132.Boivin N, Sergeric Y, Rivest S, Boivin G. Effect of pretreatment with Toll-like receptor agonists in a mouse model of Herpes simplex virus type 1 encephalitis. J Infect Dis. 2008;198:664–672. doi: 10.1086/590671. [DOI] [PubMed] [Google Scholar]

[CR133] 133.Pop E. Dexanabinol Pharmos. Curr Opin Investig Drugs. 2000;1:494–503. [PubMed] [Google Scholar]

[CR134] 134.Darlington CL. Dexanabinol: a novel cannabinoid with neuroprotective properties. IDrugs. 2003;6:976–979. [PubMed] [Google Scholar]

[CR135] 135.Shohami E, Novikov M, Mechoulam R. A nonpsychotropic cannabinoid, HU-211, has cerebrovascular effects after closed head injury in the rat. J Neurotrauma. 1993;10:109–119. doi: 10.1089/neu.1993.10.109. [DOI] [PubMed] [Google Scholar]

[CR136] 136.Belayev L, Busto R, Zhao W, Ginsberg MD. HU-211, a novel noncompetitive N-methyl-d-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke. 1995;26:2313–2319. doi: 10.1161/01.str.26.12.2313. [DOI] [PubMed] [Google Scholar]

[CR137] 137.Feigenbaum JJ, Bergmann F, Richmond SA, et al. Nonpsychotropic cannabinoid acts as a functional N-methyl-d-aspartate receptor blocker. Proc Natl Acad Sci U S A. 1989;86:9584–9987. doi: 10.1073/pnas.86.23.9584. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR138] 138.Eshhar N, Striem S, Kohen R, Tirosh O, Biegon A. Neuroprotectant and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur J Pharmacol. 1995;283:19–29. doi: 10.1016/0014-2999(95)00271-l. [DOI] [PubMed] [Google Scholar]

[CR139] 139.Shohami E, Gallily R, Mechoulam R, Bass R, Ben Hur T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant. J Neuroimmunol. 1997;72:169–177. doi: 10.1016/s0165-5728(96)00181-6. [DOI] [PubMed] [Google Scholar]

[CR140] 140.Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med. 2002;8:58–61. doi: 10.1016/s1471-4914(02)02276-1. [DOI] [PubMed] [Google Scholar]

[CR141] 141.Knoller N, Levi L, Shoshan I, et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med. 2002;30:548–554. doi: 10.1097/00003246-200203000-00009. [DOI] [PubMed] [Google Scholar]

[CR142] 142.Maas AI, Murray G, Henney H, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 2006;5:38–45. doi: 10.1016/S1474-4422(05)70253-2. [DOI] [PubMed] [Google Scholar]

[CR143] 143.Vink R, Nimmo AJ. Novel therapies in development for the treatment of traumatic brain injury. Expert Opin Investig Drugs. 2002;11:1375–1386. doi: 10.1517/13543784.11.10.1375. [DOI] [PubMed] [Google Scholar]

[CR144] 144.Hoane MR. Assessment of cognitive function following magnesium therapy in the traumatically injured brain. Magnes Res. 2007;20:229–236. [PubMed] [Google Scholar]

[CR145] 145.Meloni BP, Zhu H, Knuckey NW. Is magnesium neuroprotective following global and focal cerebral ischaemia? A review of published studies. Magnes Res. 2006;19:123–137. [PubMed] [Google Scholar]

[CR146] 146.Haupt H, Scheibe F, Mazurek B. Therapeutic efficacy of magnesium in acoustic trauma in the guinea pig. ORL J Otorhinolaryngol Relat Spec. 2003;65:134–139. doi: 10.1159/000072250. [DOI] [PubMed] [Google Scholar]

[CR147] 147.Hoane MR, Knotts AA, Akstulewicz SL, Aquilano M, Means LW. The behavioral effects of magnesium therapy on recovery of function following bilateral anterior medial cortex lesions in the rat. Brain Res Bull. 2003;15:105–114. doi: 10.1016/s0361-9230(03)00022-4. [DOI] [PubMed] [Google Scholar]

[CR148] 148.Türkyilmaz C, Türkyilmaz Z, Atalay Y, Söylemezoglu F, Celasun B. Magnesium pre-treatment reduces neuronal apoptosis in newborn rats in hypoxia-ischemia. Brain Res. 2002;955:133–137. doi: 10.1016/s0006-8993(02)03395-4. [DOI] [PubMed] [Google Scholar]

[CR149] 149.Tang YN, Zhao FL, Ye HM. Expression of caspase-3 mRNA in the hippocampus of seven-day-old hypoxic-ischemic rats and the mechanism of neural protection with magnesium sulfate [In Chinese] Zhonghua Er Ke Za Zhi. 2003;41:212–214. [PubMed] [Google Scholar]

[CR150] 150.Gee JB, Corbett RJ, Perlman J, Laptook AR. The effects of systemic magnesium sulfate infusion on brain magnesium concentrations and energy state during hypoxia-ischemia in newborn miniswine. Pediatr Res. 2004;55:93–100. doi: 10.1203/01.PDR.0000099771.39629.E5. [DOI] [PubMed] [Google Scholar]

[CR151] 151.Lee JS, Han YM, Yoo do S, et al. A molecular basis for the efficacy of magnesium treatment following traumatic brain injury in rats. J Neurotrauma. 2004;21:549–561. doi: 10.1089/089771504774129883. [DOI] [PubMed] [Google Scholar]

[CR152] 152.Xu M, Dai W, Deng X. Effects on magnesium sulfate on brain mitochondrial respiratory function in rats after experimental traumatic brain injury. Chin J Traumatol. 2002;5:361–364. [PubMed] [Google Scholar]

[CR153] 153.Sang N, Meng Z. Blockade by magnesium of sodium currents in accutely isolated hippocampal CA1 neurons of rat. Brain Res. 2002;18:218–221. doi: 10.1016/s0006-8993(02)03217-1. [DOI] [PubMed] [Google Scholar]

[CR154] 154.Okiyama K, Smith DH, Gennarelli TA, Simon RP, Leach M, McIntosh TK. The sodium channel blocker and glutamate release inhibitor BW1003C87 and magnesium attenuate regional cerebral edema following experimental brain injury in the rat. J Neurochem. 1995;64:802–809. doi: 10.1046/j.1471-4159.1995.64020802.x. [DOI] [PubMed] [Google Scholar]

[CR155] 155.Kahraman S, Ozgurtas T, Kayali H, Atabey C, Kutluay T, Timurkaynak E. Monitoring of serum ionized magnesium in neurosurgical intensive care unit: preliminary results. Clin Chem Acta. 2003;334:211–215. doi: 10.1016/s0009-8981(03)00235-3. [DOI] [PubMed] [Google Scholar]

[CR156] 156.van den Burgh WM, Algra A, van der Sprenkel JW, Tullenken CA, Rinkel GJ. Hypomagnesia after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2003;52:276–281. doi: 10.1227/01.neu.0000043984.42487.0e. [DOI] [PubMed] [Google Scholar]

[CR157] 157.Stippler M, Fischer MR, Puccio AM, et al. Serum and cerebrospinal fluid magnesium in severe traumatic brain injury outcome. J Neurotrauma. 2007;24:1347–1354. doi: 10.1089/neu.2007.0277. [DOI] [PubMed] [Google Scholar]

[CR158] 158.Kafadar AM, Sanus GZ, Is M, et al. Prolonged elevation of magnesium in the cerebrospinal fluid of patients with severe head injury. Neurol Res. 2007;29:824–829. doi: 10.1179/016164107X181879. [DOI] [PubMed] [Google Scholar]

[CR159] 159.Heath DL, Vink R. Subdural hematoma following traumatic brain injury causes a secondary decline in brain free magnesium concentration. J Neurotrauma. 2001;18:465–469. doi: 10.1089/089771501750171074. [DOI] [PubMed] [Google Scholar]

[CR160] 160.Altura BM, Kostellow AB, Zhang A, et al. Expression of the nuclear factor-κB and proto-oncogenes c-fos and c-jun are induced by low extracellular Mg2+ in aortic and cerebral vascular smooth muscle cells: possible links to hypertension, atherogenesis and stroke. Am J Hypertension. 2003;16:701–707. doi: 10.1016/s0895-7061(03)00987-7. [DOI] [PubMed] [Google Scholar]

[CR161] 161.McKee JA, Brewer RP, Macy GE, et al. Analysis of the brain bioavailability of peripherally administered magnesium sulfate: a study in humans with acute brain injury undergoing prolonged induced hypermagnesemia. Crit Care Med. 2005;33:661–666. doi: 10.1097/01.ccm.0000156293.35868.b2. [DOI] [PubMed] [Google Scholar]

[CR162] 162.Temkin NR, Anderson GD, Winn HR, et al. Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol. 2007;6:29–38. doi: 10.1016/S1474-4422(06)70630-5. [DOI] [PubMed] [Google Scholar]

[CR163] 163.Maas AI, Murray GD. Magnesium for neuroprotection after traumatic brain injury. Lancet Neurol. 2007;6:20–21. doi: 10.1016/S1474-4422(06)70668-8. [DOI] [PubMed] [Google Scholar]

[CR164] 164.Heath DL, Vink R. Optimization of magnesium therapy after severe diffuse axonal brain injury in rats. J Pharmacol Exp Ther. 1999;288:1311–1316. [PubMed] [Google Scholar]

[CR165] 165.Aslanyan S, Weir CJ, Muir KW, Lees KR, IMAGES Study Investigators Magnesium for treatment of acute lacunar stroke syndromes: further analysis of the IMAGES trial. Stroke. 2007;38:1269–1273. doi: 10.1161/01.STR.0000259628.94421.09. [DOI] [PubMed] [Google Scholar]

[CR166] 166.Manet S, Marpeau L, Zupan-Simunek V, PREMAG Trial Group et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. BJOG. 2007;114:310–318. doi: 10.1111/j.1471-0528.2006.01162.x. [DOI] [PubMed] [Google Scholar]

[CR167] 167.Thal SC, Engelhard K, Werner C. New cerebral protection strategies. Curr Opin Anaesthesiol. 2005;18:490–495. doi: 10.1097/01.aco.0000182561.32680.30. [DOI] [PubMed] [Google Scholar]

[CR168] 168.Bhudia SK, Cosgrove DM, Naugle RI, et al. Magnesium as a neuroprotectant in cardiac surgery: a randomized clinical trial. J Thorac Cardiovasc Surg. 2006;131:853–861. doi: 10.1016/j.jtcvs.2005.11.018. [DOI] [PubMed] [Google Scholar]

[CR169] 169.Kaminska B, Gaweda-Walerych K, Zawadzka M. Molecular mechanisms of neuroprotective action of immunosuppressants: facts and hypotheses. J Cell Mol Med. 2004;8:45–48. doi: 10.1111/j.1582-4934.2004.tb00259.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR170] 170.Riess P, Bareyre FM, Saatman KE, et al. Effects of chronic, post-injury cyclosporin A administration on motor and sensorimotor function following severe, experimental traumatic brain injury. Restor Neurol Neurosci. 2001;18:1–8. [PubMed] [Google Scholar]

[CR171] 171.Alessandri B, Rice AC, Levasseur J, DeFord M, Hamm RJ, Bullock RM. Cyclosporin A improves brain tissue oxygen consumption and learning/memory performance after lateral fluid percussion injury in rats. J Neurotrauma. 2002;19:829–841. doi: 10.1089/08977150260190429. [DOI] [PubMed] [Google Scholar]

[CR172] 172.Szabo I, Zoratti M. The giant channel of the inner mitochondrial membrane is inhibited by cyclosporin A. J Biol Chem. 1991;266:3376–3379. [PubMed] [Google Scholar]

[CR173] 173.Sullivan PG, Thompson MB, Scheff SW. Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. Exp Neurol. 1999;160:226–234. doi: 10.1006/exnr.1999.7197. [DOI] [PubMed] [Google Scholar]

[CR174] 174.Nakai A, Shibazaki Y, Taniuchi Y, Miyake H, Oya A, Takeshita T. Role of mitochondrial permeability transition in fetal brain damage in rats. Pediatr Neurol. 2004;30:247–253. doi: 10.1016/j.pediatrneurol.2003.09.006. [DOI] [PubMed] [Google Scholar]

[CR175] 175.Panickar KS, Jayakumar AR, Norenberg MD. Differential response of neural cells to trauma-induced free radical production in vitro. Neurochem Res. 2002;27:161–166. doi: 10.1023/a:1014875210852. [DOI] [PubMed] [Google Scholar]

[CR176] 176.Mirzayan MJ, Klinge PM, Ude S, et al. Modified calcium accumulation after controlled cortical impact under cyclosporin A treatment: a 45Ca autoradiographic study. Neurol Res. 2008;30:476–479. doi: 10.1179/174313208X276916. [DOI] [PubMed] [Google Scholar]

[CR177] 177.Uchino H, Ishii N, Shibasaki F. Calcineurin and cyclophilin D are differential targets of neuroprotection by immunosuppressants CsA and FK506 in ischemic brain damage. Acta Neurochir Suppl. 2003;86:105–111. doi: 10.1007/978-3-7091-0651-8_24. [DOI] [PubMed] [Google Scholar]

[CR178] 178.Mbye LH, Singh IN, Carrico KM, Saatman KE, Hall ED. Comparative neuroprotective effects of cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury. J Cereb Blood Flow Metab 2008 Aug. 20 [Epub ahead of print]. [DOI] [PMC free article] [PubMed]

[CR179] 179.Uchino H, Minamikawa-Tachino R, Kristian T, et al. Differential neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability transition. Neurobiol Dis. 2002;10:219–233. doi: 10.1006/nbdi.2002.0514. [DOI] [PubMed] [Google Scholar]

[CR180] 180.Domañska-Janik K, Buzañska L, Dłuzniewska J, Kozłowska H, Samowska A, Zabłocka B. Neuroprotection by cyclosporin A following transient brain ischemia correlates with the inhibition of the early efflux of cytochrome C to cytoplasm. Brain Res Mol Brain Res. 2004;121:50–59. doi: 10.1016/j.molbrainres.2003.11.006. [DOI] [PubMed] [Google Scholar]

[CR181] 181.Ferrand-Drake M, Zhu C, Gido G, et al. Cyclosporin A prevents calpain activation despite increased intracellular calcium concentrations, as well as translocation of apoptosis-inducing factor, cytochrome c and caspase-3 activation in neurons exposed to transient hypoglycemia. J Neurochem. 2003;85:1431–1442. doi: 10.1046/j.1471-4159.2003.01794.x. [DOI] [PubMed] [Google Scholar]

[CR182] 182.Santos JB, Schauwecker PE. Protection provided by cyclosporin A against excitotoxic neuronal death is genotype specific. Epilepsia. 2003;44:995–1002. doi: 10.1046/j.1528-1157.2003.66302.x. [DOI] [PubMed] [Google Scholar]

[CR183] 183.Van Den Heuvel C, Donkin JJ, Finnic JW, et al. Downregulation of amyloid precursor protein (APP) expression following post-traumatic cyclosporin-A administration. J Neurotrauma. 2004;21:1562–1572. doi: 10.1089/neu.2004.21.1562. [DOI] [PubMed] [Google Scholar]

[CR184] 184.Okonkwo DO, Melon DE, Pellicane AJ, et al. Dose-response of cyclosporin A in attenuating traumatic axonal injury in rat. Neuro Report. 2003;14:463–466. doi: 10.1097/00001756-200303030-00033. [DOI] [PubMed] [Google Scholar]

[CR185] 185.Buki A, Okonkwo DO, Povlishock JT. Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury. J Neurotrauma. 1999;16:511–521. doi: 10.1089/neu.1999.16.511. [DOI] [PubMed] [Google Scholar]

[CR186] 186.Okonkwo DO, Povlishock JT. An intrathecal bolus of cyclosporin A before injury preserves mitochondrial integrity and attenuates axonal disruption in traumatic brain injury. J Cereb Blood Flow Metab. 1999;19:443–451. doi: 10.1097/00004647-199904000-00010. [DOI] [PubMed] [Google Scholar]

[CR187] 187.Okonkwo DO, Buki A, Siman R, Povlishock JT. Cyclosporin A limits calcium-induced axonal damage following traumatic brain injury. NeuroReport. 1999;10:353–358. doi: 10.1097/00001756-199902050-00026. [DOI] [PubMed] [Google Scholar]

[CR188] 188.Suehiro E, Singleton RH, Stone JR, Povlishock JT. The immunophilin ligand FK506 attenuated the axonal damage associated with rapid rewarming following posttraumatic hypothermia. Exp Neurol. 2001;172:199–210. doi: 10.1006/exnr.2001.7765. [DOI] [PubMed] [Google Scholar]

[CR189] 189.Empey PE, McNamara PJ, Young B, Rosbolt MB, Hatton J. Cyclosporin A disposition following acute traumatic brain injury. J Neurotrauma. 2006;23:109–116. doi: 10.1089/neu.2006.23.109. [DOI] [PubMed] [Google Scholar]

[CR190] 190.Mazzeo AT, Alves OL, Gilman CB, et al. Brain metabolic and hemodynamic effects of cyclosporin A after human severe traumatic brain injury: a microdialysis study. Acta Neurochir (Wien) 2008;150:1019–1031. doi: 10.1007/s00701-008-0021-7. [DOI] [PubMed] [Google Scholar]

[CR191] 191.Faden AI. Role of thyrotropin-releasing hormone and opiate receptor antagonists in limiting central nervous system injury. Adv Neurol. 1988;47:531–546. [PubMed] [Google Scholar]

[CR192] 192.McIntosh TK, Vink R, Faden AI. An analog of thyrotropin-releasing hormone improves outcome after traumatic brain injury: 31P NMR studies. Am J Physiol. 1988;254:R785–R792. doi: 10.1152/ajpregu.1988.254.5.R785. [DOI] [PubMed] [Google Scholar]

[CR193] 193.Vink R, McIntosh TK, Faden AI. Treatment with the thyrotropin-releasing hormone analog CG3703 restores magnesium homeostasis following traumatic brain injury in rats. Brain Res. 1988;460:184–188. doi: 10.1016/0006-8993(88)91221-8. [DOI] [PubMed] [Google Scholar]

[CR194] 194.Dewitt DS, Rough DS, Uchida T, Deal DD, Vines SM. Effects of nalmefene, CG3703, tirilazad, or dopamine on cerebral blood flow, oxygen delivery, and electroencephalographic activity after traumatic brain injury and hemorrhage. J Neurotrauma. 1997;14:931–941. doi: 10.1089/neu.1997.14.931. [DOI] [PubMed] [Google Scholar]

[CR195] 195.Maejima S, Katayama Y. Neurosurgical trauma in Japan. World J Surg. 2001;25:1205–1209. doi: 10.1007/s00268-001-0083-7. [DOI] [PubMed] [Google Scholar]

[CR196] 196.Faden AI, Fox GB, Fan L, et al. Novel TRH analog improves motor and cognitive recovery after traumatic brain injury in rodents. Am J Physiol. 1999;277:R1196–R1204. doi: 10.1152/ajpregu.1999.277.4.R1196. [DOI] [PubMed] [Google Scholar]

[CR197] 197.Faden AI, Movsesyan VA, Knoblach SM, Ahmed F, Cernak I. Neuroprotective effects of novel small peptides in vitro and after brain injury. Neuropharmacology. 2005;49:410–424. doi: 10.1016/j.neuropharm.2005.04.001. [DOI] [PubMed] [Google Scholar]

[CR198] 198.Niu GM, Gu XJ, Su YL, Wan F, Su FZ, Xue DL. Effect of thyrotropin-releasing hormone on cerebral free radical reactions following acute brain injury in rabbits. Chin J Traumatol. 2003;6:104–106. [PubMed] [Google Scholar]

PERMALINK

Multifunctional drugs for head injury

Robert Vink

Alan J Nimmo

Summary

References

ACTIONS

PERMALINK

RESOURCES

Cite

Add to Collections

PERMALINK

Multifunctional drugs for head injury

Robert Vink

Alan J Nimmo

Summary

References

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases